| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | IMM-529 Recurrent Clostridioides difficile infection (CDI) | Phase 2 | — | Biologics | Infectious Diseases | ||
Phase 2 data readout example | IMM-529 Recurrent Clostridioides difficile infection (CDI) | Phase 2 | — | Biologics | Infectious Diseases | ||
Phase 2 data readout example | IMM-529 Recurrent Clostridioides difficile infection (CDI) | Phase 2 | — | Biologics | Infectious Diseases |
Recent Updates
Recently added Catalysts
Immuron Limited$1.1
-0.01 (-0.9%)
C 45Pipeline Score Fair Value Pharma · Clinical
Market Cap
7.45 M
EPS
-0.48
P/E Ratio
-
Value Trade
138.01 K
-4.76 %
Week
8.21 %
1 Month
36.99 %
3 Month
-37.5 %
6 Month
-80.12 %
5 Year
-89.19 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
11.87 K
52 Week Range
0.68 - 2.39
% held by Insiders
-
% held by Institutions
1.04 %
Enterprise Value
781.27 K
Total Shares
8.17 M
Short %
4.4 %
Float Shares
-
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C45
Pipeline Score $11M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.5x
rNPV / MCap Top 68%
Micro Cap (rank 291 of 905)
Percentile RankImmuron Limited carries a moderate pipeline score (45/100), with $4.5B risk-adjusted pipeline value, led by IMM-124E in Nonalcoholic Fatty Liver Disease (NAFLD) (Phase 2), across $71B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMM-124E Monoclonal antibody | Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | NCT03042767 | 60% | $2.4B | COMPLETED | 40 | - | - | Oct 23, 2019 | - | May 24, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IMM-529 | Clostridioides difficile infection (CDI),prevention of recurrent CDI (rCDI) | Phase 2 | 2025-10-08 | |||
IMM-529 | Clostridioides difficile infection (CDI),prevention of recurrent CDI (rCDI) | Phase 2 | 2025-10-08 | |||
IMM-529 | Clostridioides difficile infection (CDI),prevention of recurrent CDI (rCDI) | Phase 2 | 2025-10-08 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMRN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IMRN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMRN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMRN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMRN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
IMRN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMRNMay 2026 Ms Melissa Kostopoulos Senior Adviser, Listings Compliance (Melbourne) ASX Limited Dear Ms Kostopoulos RE: Immuron Limited ( IMC'): Response to Price Query I refer to your letter dated 28 May 2026 regarding IMC'
Immuron Limited (IMC; NASDAQ: IMRN) received a price query letter from ASX's Listings Compliance regarding its recent trading activity. In response, the company affirmed that it is not aware of any undisclosed information that would explain this trading. The response also indicates that the company is compliant with Listing Rules. However, IMC must ensure timely communication with ASX to avoid potential trading suspension or compliance issues.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Melbourne, Australia, May 8 , 2026 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore
Immuron Limited's CEO Steven Lydeamore presented virtually at the Emerging Growth Conference on May 7, 2026. The presentation underscores Immuron's commitment to developing targeted oral therapies for infectious diseases, such as their flagship product Travelan, which aims to prevent travelers' diarrhea. The company's innovative use of polyclonal antibodies derived from bovine colostrum was emphasized, showcasing their platform technology's versatility in addressing gastrointestinal health. This event represents an opportunity for the company to increase its profile and establish new business relationships.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Melbourne, Australia
Immuron Limited's CEO, Steven Lydeamore, is set to present at the Emerging Growth Conference on May 7, 2026, highlighting the company's advancements in biopharmaceuticals. Immuron focuses on developing targeted polyclonal antibodies for infectious diseases, with notable products like Travelan for preventing travelers' diarrhea. Moreover, the company is exploring new treatments such as IMM-529 for recurrent Clostridioides difficile infections, showing promise in pre-clinical trials. This conference presentation offers a platform for potential investors and stakeholders to learn about Immuron's progress and future initiatives.
Read more →IMRNEmerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00
Emerging Growth Research has released a Flash Report on Immuron, maintaining a Buy-Extended rating and raising the 12-month price target to $4.00 from $3.90. The report highlights Immuron's double-digit revenue growth, particularly in Australia and the U.S., and strong performance in Canada. The company is advancing its clinical pipeline, including candidates for travelers' diarrhea and C. difficile infections, with FDA clearance for Phase 2 trials.
Read more →IMRNImmuron Double Digit 3Q Sales Growth
Immuron Limited reported a 16% increase in Q3 sales, reaching AUD$1.5 million, driven by effective marketing strategies and expansion into new markets. The company noted significant growth in sales of its product Travelan®, particularly in Canada, though some regions experienced declines year-to-date. The strengthening Australian dollar has impacted U.S. sales, highlighting the challenges of currency fluctuations.
Read more →IMRNASX/NASDAQ Announcement Immuron Double Digit 3Q Sales Growth Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp) YTD Mar 2026 sales AUD$5.7 million up 7% on prior compar
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced a 16% increase in global Q3 sales, totaling AUD$1.5 million. The growth is attributed to effective marketing strategies, including increased promotion in existing stores and new listings in Canada. In the U.S., sales remained relatively stable with a 1% increase due to various marketing initiatives. However, the strengthening of the Australian dollar against the U.S. dollar has negatively influenced sales figures. Overall, the company is seeing positive momentum for its Travelan product in key markets.
Read more →IMRNASX Announcement 13 April 2026 Small Holding Share Sale Facility Immuron Limited (ASX:IMC and NASDAQ: IMRN) (Immuron or the Company) is pleased to announce that it is providing eligible holders of small parcels of ordina
Immuron Limited has announced the establishment of a Small Holding Share Sale Facility for shareholders holding less than $500 worth of ordinary shares. This initiative will enable eligible shareholders to sell their small holdings without incurring any brokerage fees, significantly reducing administrative costs for the company. Shareholders must opt out by a specified date if they do not wish to sell. This program addresses the needs of nearly 1,500 shareholders with small holdings, providing a cost-effective solution for disposing of shares.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference
Immuron Limited's CEO, Steven Lydeamore, will present virtually at the Coffee Microcaps Conference on March 5, 2026. The company specializes in developing targeted polyclonal antibodies for infectious diseases, including its product Travelan®, which helps prevent travelers' diarrhea. The presentation will highlight Immuron's advancements and product offerings.
Read more →IMRNImmuron Limited Appendix 4D Half-year report 1. Company details Name of entity: Immuron Limited ABN: 80 063 114 045 Reporting period: For the period ended 31 December 2025 Previous period: For the period ended 31 Decembe
Immuron Limited has released its half-year report for the period ending December 31, 2025, indicating a 4.8% increase in revenue to A$4,184,357 and a 22.9% reduction in losses. Although net tangible assets dropped to 3.94 cents per share, the company highlighted record sales of Hyperimmune products and received FDA approval for its IMM-529 IND application. This approval is pivotal for advancing studies on treating Clostridioides difficile infection, a significant health threat.
Read more →IMRNImmuron Reports HY26 Results and Strategic Reset
Immuron Limited has announced its half-year financial results and a strategic reset, highlighting advancements in its product pipeline, particularly with Travelan and IMM-529. The company is focused on developing targeted polyclonal antibodies for infectious diseases. Positive pre-clinical results for IMM-529 suggest promising potential in treating recurrent Clostridioides difficile infections.
Read more →IMRNASX Announcement Immuron receives R&D Tax Incentive Melbourne, Australia
Immuron Limited has announced that it received A$1,121,885 in R&D Tax Incentive from the Australian Government for the financial year ending June 30, 2025. This funding will act as non-dilutive support, enabling the company to invest further in growth opportunities, particularly within their Hyper-Immune product line. The focus remains on improving profitability while implementing cost reduction strategies to enhance earnings before interest, tax, depreciation, and amortization, excluding R&D expenses. Immuron continues to develop orally delivered targeted polyclonal antibodies for various infectious diseases, particularly for travelers' diarrhea.
Read more →IMRNASX/NASDAQ Announcement 12 February 2026 2026 Extraordinary General Meeting Results In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 Immuron Limited (ASX: IMC; NASDAQ: IMRN or the
Immuron Limited announced that all resolutions proposed during the 2026 Extraordinary General Meeting were passed by shareholders. The meeting, conducted in accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001, showcases the company's commitment to its growth strategy. Immuron focuses on developing orally delivered targeted polyclonal antibodies derived from engineered bovine colostrum aimed at treating infectious diseases. The company continues to explore opportunities within its proprietary technology framework, which may allow for effective interventions against various pathogens.
Read more →IMRNASX Announcement 9 February 2026 Resignation/Appointment of Company Secretary and Chief Financial Officer Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises, in accordance with ASX Listing Rule 3.16.1, that Mr Phillip Hain
Immuron Limited has announced the resignation of Chief Financial Officer and Company Secretary Phillip Hains, effective February 9, 2026. The board expressed gratitude for his contributions since 2013. In his place, Olga Smejkalova has been appointed as Company Secretary, while Aaron Laurita will take on the role of Chief Financial Officer, both effective the same date. The appointments are expected to enhance the company's governance and financial management.
Read more →IMRNImmuron Reports Continued Sales Growth
Immuron Limited has reported continued sales growth for its immune supplement Travelan®, with an 11% increase in Australia and a 17% increase in the U.S. The company successfully launched ProIBS® ahead of schedule and is expanding its presence in Canada. Marketing initiatives and increased consumer awareness have contributed to this growth, despite some challenges such as stock reductions from a key distributor.
Read more →IMRNASX Announcement Immuron Continued Sales Growth Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp) Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AU
Immuron Limited reported a 5% increase in global sales for the first half of the year, reaching AUD$4.2 million. The company experienced notable growth in Australia, with Q2 sales up by 11%. The recent launch of ProIBS, which is gaining traction in major pharmacy chains, is expected to drive future growth. However, Immuron faced a significant drop in Canadian sales by 85% compared to the previous period, highlighting challenges in that market.
Read more →IMRNImmuron CEO, Steven Lydeamore to present at Emerging Growth Conference Melbourne, Australia
Immuron Limited has announced that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on January 22, 2026. The conference will provide insights into the company’s focus on developing orally delivered polyclonal antibodies aimed at treating infectious diseases. Notably, Immuron's product, Travelan, is aimed at preventing travelers' diarrhea, and the company continues to innovate with additional therapies targeting various gastrointestinal disorders.
Read more →IMRNIMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF EXTRAORDINARY GENERAL MEETING AND EXPLANATORY STATEMENT Date and Time of Meeting: Thursday, 12 February 2026 at 11.00 am AEDT Place of Meeting:
IMMURON LIMITED has announced an Extraordinary General Meeting scheduled for February 12, 2026, at 11:00 am AEDT. The meeting will be held at Level 3, 62 Lygon Street, Carlton, VIC 3053. Shareholders are encouraged to attend in person or vote by proxy, with detailed voting instructions provided in the accompanying Explanatory Statement. The meeting will address resolutions including the ratification of prior share issuances under Listing Rule 7.1 and Listing Rule 7.1A.
Read more →IMRNAppendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Tuesday
Immuron Limited announced an application for the quotation of 314,843 ordinary fully paid shares on December 16, 2025. The announcement includes details on the conversion of existing performance rights into additional ordinary shares. Following this application, the total number of ordinary fully paid shares on issue is expected to rise to 325,510,700. The conversion of securities is part of an ongoing program to manage capital and incentivize employees.
Read more →IMRNAppendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Thursday
Immuron Limited has applied for the quotation of additional securities on the ASX, following the exercise of options and conversion of performance rights. A total of 1,874,964 ordinary shares are set to be quoted, which will contribute to the company's capital structure. This announcement highlights the ongoing adjustments in the company’s equity, as it reinforces its commitment to operational engagements and shareholder interests.
Read more →IMRNUniformed Services University to Release Topline Data Highlights: Primary Endpoint did not reach statistical significance Investigational product was manufactured by a third party and was not administered in accordance w
Immuron Limited announced that the Uniformed Services University released topline results from a clinical trial evaluating the investigational product IMM-124E, which did not meet the primary endpoint's statistical significance. The study found differences in administration compared to Immuron's product, Travelan, impacting the trial's outcomes. Immuron noted that it does not consider the trial's results representative of Travelan's efficacy. Moving forward, the company plans to refine its clinical trial design and stick with established dosing recommendations.
Read more →IMRNAppendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday
IMMURON LIMITED has announced the quotation of 45,472,000 ordinary fully paid securities, which will be listed on the ASX under the code IMC. This issuance is part of a prior transaction disclosed in Appendix 3B. The securities are being issued at AUD 0.0791 each, reflecting a strategic move to strengthen the company's financial position. This action signifies the company's commitment to enhance shareholder value and capital base.
Read more →IMRNAppendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 4/12/2025 The Proposed issue is: A placement or other type of issue
Immuron Limited has announced a proposed issue of 45,472,000 ordinary fully paid securities through a placement or other type of issue. This announcement includes details regarding the entity's compliance with ASX listing rules and the intention to apply for quotation of the securities. While the specifics of any required approvals or conditions prior to the issue are discussed, no external approvals have been explicitly mentioned. The entity's rationale for choosing a placement over other funding options is noted but not detailed in the announcement.
Read more →IMRNASX Announcement 4 December 2025 CHANGE OF PROVIDER OF SHARE REGISTRY MANAGEMENT SERVICES FOR IMMURON LIMITED In accordance with listing rule 3.15.1, Immuron Limited (ASX: IMC , NASDAQ : IMRN or the Company) advises that
Immuron Limited has announced a transition from Automic Group to Boardroom Pty Limited for share registry management services, effective December 8, 2025. This change aligns with their compliance to listing rule 3.15.1. The transition period will see Automic Group ceasing their services on December 5, 2025, leaving a brief window for the handover. Immuron is known for developing therapies for infectious diseases, particularly focusing on their product Travelan, which helps prevent travelers' diarrhea.
Read more →IMRNImmuron New U.S. Department of Defense Award & Clinical Trial Update
Immuron Limited has announced a new research agreement with the U.S. Department of Defense to develop two oral therapeutics targeting Campylobacter and Shigella. This initiative aims to create vaccines in collaboration with military research institutions, utilizing Immuron's proprietary technology to produce hyper-immune bovine colostrum products. In addition, results from a clinical trial evaluating the effectiveness of its E. coli hyperimmune colostrum called Travelan are anticipated soon, aiming to address the significant health risks posed by infectious diarrhea, particularly among deployed military personnel.
Read more →IMRNConfidential Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Informatio
Immuron Limited has reported changes in director interests, with notable acquisitions by directors. Daniel Pollock increased his options from 1,000,000 to 2,000,000, while Ravi Savarirayan made similar changes. Dr. Jeannette Joughin also increased her holding in unlisted options. These changes were precipitated by shareholder resolutions approved at the recent Annual General Meeting. All required disclosures have been made in accordance with ASX listing rules.
Read more →IMRNASX/NASDAQ Announcement 11 November 2025 2025 Annual General Meeting - CEO Address Immuron Limited (ASX: IMC; NASDAQ: IMRN) attaches the CEO Address to be delivered by Chief Executive Officer, Steve Lydeamore, at this mo
Immuron Limited announced significant revenue growth and operational highlights during its 2025 Annual General Meeting, led by CEO Steve Lydeamore. The company reported a 49% increase in global sales revenue for FY25, with notable success in North America. Furthermore, Immuron achieved FDA approval for its IMM-529 IND and completed a Phase 2 trial for Travelan with statistically significant results. However, ongoing challenges include high operational expenses and a dependence on third-party suppliers for production.
Read more →IMRNAppendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 6/11/2025 The Proposed issue is: A placement or other type of issue
Immuron Limited has announced a proposed issuance of 8,495,080 ordinary fully paid securities. This placement aims to secure funds, pending compliance with ASX listing rules. The securities will rank equally with existing issued securities in the same class. The prospectus details are intended for potential investors once finalized.
Read more →IMRNImmuron IMM-529 IND approved by FDA
Immuron Limited has received FDA approval for its Investigational New Drug application for IMM-529, allowing the initiation of a Phase 2 clinical trial targeting Clostridioides difficile infection. The trial will assess the safety and efficacy of IMM-529 in combination with standard care. If successful, IMM-529 could significantly impact the treatment landscape for CDI, with a projected annual revenue of $400 million.
Read more →IMRNImmuron IMM-529 IND approved by FDA Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceed FDA assigned an IND n
Immuron Limited has received FDA approval for its Investigational New Drug application for IMM-529, allowing the company to proceed with a Phase 2 clinical trial targeting Clostridioides difficile infections (CDI). The trial aims to evaluate the safety and efficacy of IMM-529 in treating both first episode and recurrent CDI. With an estimated market of approximately 98,000 patients eligible for treatment, IMM-529 could significantly impact the standard of care for CDI. The oral dosing formulation of IMM-529, developed in collaboration with Monash University, is expected to provide a new adjunctive therapy in combating CDI and its recurrence.
Read more →IMRNImmuron Announces Clinical Trial Update
Immuron Limited has provided a clinical trial update regarding its products Travelan® and IMM-529. The company submitted an IND application for IMM-529 to the FDA, which is currently under review. Additionally, delays in receiving results from a related study have pushed the expected timeline for topline results to November 2025. The outcomes of these studies will influence Immuron's future dosing strategies.
Read more →IMRNImmuron Announces Clinical Trial Update IMM-529 IND: currently under review, FDA request for Information - minor updates to clinical protocol completed and submitted Travelan P2TD (n=851) Uniformed Services University st
Immuron Limited has provided a clinical trial update regarding its products, IMM-529 and Travelan. The IND application for IMM-529 targeting Clostridioides difficile has been submitted and is currently under FDA review, with Immuron addressing additional queries from the agency. Meanwhile, results from the ongoing Travelan P2TD study have been delayed until the end of November 2025, which is crucial for determining dosing strategies in upcoming discussions with the FDA. The successful progression of these clinical trials is vital for Immuron's pipeline.
Read more →IMRNAppendix 3H - Notification of cessation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Monday
Immuron Limited has announced the cessation of 500,000 options that were set to expire on various dates at various prices. This decision comes without any exercise or conversion of the options, which may influence investor sentiment negatively and reflect on the company's capital structure. Following this adjustment, the total issued capital will consist of a revised number of equity and debt securities. Investors will be closely monitoring the implications of this cessation on the firm's future performance.
Read more →IMRNImmuron launch PROIBS for Irritable Bowel Syndrome (IBS) Melbourne, Australia
Immuron Limited has officially launched its new product, PROIBS, aimed at treating symptoms of medically diagnosed Irritable Bowel Syndrome (IBS), in the Australian market. The company has already received orders from pharmacies and anticipates a positive consumer response. This launch comes ahead of the festive season, a peak time for IBS symptom triggers, and will be supported by a digital marketing campaign to raise awareness. The IBS treatment market in Australia is projected to grow, providing a favorable environment for the new product.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia
Immuron Limited's CEO, Steven Lydeamore, will present virtually at the Emerging Growth Conference on October 22, 2025. The company focuses on developing targeted polyclonal antibodies, particularly for the treatment of infectious diseases like travelers' diarrhea and recurrent C. difficile infections. Their products, such as Travelan and IMM-529, utilize unique proprietary technology based on polyclonal immunoglobulins derived from hyper-immune bovine colostrum. This presentation aims to showcase Immuron's advancements and potential in the biopharmaceutical sector.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation to AusBiotech Invest 2025 conference Melbourne, Australia
Immuron Limited, represented by CEO Steven Lydeamore, will present at the AusBiotech Invest conference in Melbourne on October 21, 2025. The company specializes in developing targeted polyclonal antibodies, particularly for treating infectious diseases. Their product, Travelan, is designed to prevent travelers' diarrhea, while IMM-529 is an adjunctive therapy for Clostridioides difficile infections. Immuron's innovative research positions it as a significant player in the biopharmaceutical industry.
Read more →IMRNAppendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Monday
Immuron Limited has announced an application for the quotation of 1,133,840 ordinary fully paid securities (IMC) on the ASX, to be issued as part of a previously announced transaction. The issue date for these securities is set for October 20, 2025. This application aligns with the ongoing efforts of the company to manage and increase its capital structure. Further details regarding the distribution and pricing are also included in the announcement.
Read more →IMRNAppendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 17/10/2025 The Proposed issue is: A placement or other type of issu
IMMURON LIMITED has announced a proposed issuance of 1,133,840 ordinary fully paid shares under ASX Listing Rules. The securities will be issued at a price of AUD 0.08860 each. The proceeds from this placement are aimed at funding further research and development activities, as well as providing ongoing working capital. The announcement signifies the company's intent to raise funds while using a low-cost facility for security issuance.
Read more →IMRNImmuron Q1 FY26 YoY growth
Immuron Limited reported strong sales growth for Travelan® in Q1 FY26, with a 34% increase in Australia and a 44% rise in the U.S. The growth is attributed to enhanced marketing efforts and increased consumer awareness. The company anticipates further sales growth in Canada as travel picks up later in the year.
Read more →IMRNASX Announcement 13 October 2025 Immuron Q1 FY26 YoY growth Sales Highlights (unaudited): Global Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp) Australia Q1 sales AUD$1.6 million up 52% on pcp Canada Q
Immuron Limited reported significant growth in its first quarter for FY26, with global sales reaching AUD$2.0 million, a 34% increase from the prior year. The substantial growth in sales was driven primarily by marketing efforts, with notable increases in Australia (52%) and the USA (44%). However, the company faced a sharp decline in Canadian sales, which decreased by 92%, attributed to seasonal factors. Despite this, there are positive expectations for an uptick in Canadian sales towards the end of the year as travel activity increases.
Read more →IMRNIMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2025 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT Date and Time of Meeting: Tuesday, 11 November 2025 at 11.15 am AEDT Place of Meeting: Th
Immuron Limited has scheduled its Annual General Meeting (AGM) for November 11, 2025, at 11:15 AM AEDT. The meeting will take place at the offices of Grant Thornton, Collins Square in Melbourne. Shareholders can attend in person or participate virtually but cannot vote through virtual attendance. Important resolutions to be voted on include the adoption of the remuneration report, the re-election of directors, and approval for issuing options to certain individuals.
Read more →IMRNImmuron Submits IMM-529 IND to FDA Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile inf
Immuron Limited has submitted an Investigational New Drug application to the FDA for its product IMM-529, aimed at treating and preventing Clostridioides difficile infections. The company plans to initiate a Phase 2 clinical trial in the first half of 2026, targeting both first episode and recurrent CDI patients. IMM-529 has demonstrated promising pre-clinical results and could potentially address a critical unmet need in the treatment landscape for CDI. If successful, its revenue potential is estimated at approximately $400 million annually, highlighting its commercial significance.
Read more →IMRNImmuron Submits IMM-529 IND to FDA
Immuron Limited has submitted an Investigational New Drug (IND) application to the FDA for IMM-529, aimed at treating and preventing Clostridioides difficile infection (CDI). The company plans to initiate a Phase 2 clinical trial in the first half of 2026, targeting both new and recurrent CDI patients. Market analysis suggests that upon demonstrating efficacy, IMM-529 could secure a significant market position, with revenue potential estimated at $400 million. The drug utilizes a unique mechanism of action that targets key virulence factors of C. diff, addressing a substantial public health need.
Read more →IMRNImmuron Letter to Shareholders – Projects Update
Immuron Limited has provided a shareholder update detailing progress across several projects, including record sales and advancements in clinical trials. The company anticipates significant market potential for its therapeutic products, particularly IMM-124E and IMM-529. Additionally, the launch of ProIBS is expected in early 2026. However, challenges related to FDA approvals and reliance on third-party suppliers remain.
Read more →IMRNRules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Immuron Limited ABN/ARBN Financial year ended: 80 063 114 045 30 June 2025 Our corporate go
Immuron Limited has released its Corporate Governance Statement, which is up to date as of September 25, 2025, and has been approved by the Board. This statement outlines the company's adherence to the ASX Corporate Governance Council principles and showcases its commitment to transparency and effective governance practices. The company has disclosed its governance structure, including measures for promoting diversity and board evaluations, ensuring it meets the ASX requirements.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation to Coffee Microcaps Conference Melbourne, Australia
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the Coffee Microcaps VIP Conference in Sydney on September 16, 2025. The presentation will likely cover the company's advancements in developing oral immunotherapy products, such as Travelan, which helps prevent travelers' diarrhea. Immuron is also focused on addressing recurrent Clostridioides difficile infections with its investigational drug, IMM-529, showcasing its commitment to innovative treatments for gastrointestinal health.
Read more →IMRNImmuron Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Immuron Limited ABN: 80 063 114 045 Reporting period: For the year ended 30 June 2025 Previous period: For the year ended 30 June 20
Immuron Limited reported its preliminary financial results for the year ending June 30, 2025. The company achieved a revenue increase of 48.6%, totaling $7,287,002, while losses reduced by 24.3% to $5,253,209. Despite the increase in revenue, the company's net tangible assets decreased significantly, which may raise concerns about its financial health moving forward. The company's cash balance declined considerably from the previous year, indicated a potential risk to its operational capacity. Further details will be included in the audited financial statements scheduled for release on September 30.
Read more →IMRNImmuron partners with InvestorHub
Immuron Limited has partnered with InvestorHub to enhance investor engagement through a new interactive hub. This initiative aims to consolidate communication and provide regular updates, including videos and educational content. The company is also preparing for significant milestones, including the FDA submission for IMM-529 and results from the Travelan clinical trial.
Read more →IMRNImmuron partners with InvestorHub Melbourne, Australia
Immuron Limited has announced a partnership with InvestorHub, a software company focused on direct-to-investor engagement. This collaboration aims to create an interactive investor hub that consolidates communication and updates with stakeholders. CEO Steven Lydeamore highlighted the initiative's importance as the company approaches several near-term milestones, including key FDA submissions and clinical trial results. The partnership reflects Immuron's commitment to improving transparency and engagement with its investors as it develops innovative treatments for infectious diseases.
Read more →IMRNAppendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name IMMURON LIMITED Date of this announcement Friday
Immuron Limited has announced the issuance of 2,147,154 performance rights as part of an employee incentive scheme, which are not intended to be quoted on the ASX. This issuance follows the company's existing class of securities under the IMCAE code and will vest upon meeting certain fiscal objectives. The enterprise has clarified that no security holder approval was necessary for this issuance, streamlining their operational processes.
Read more →IMRNAppendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Sunday
Immuron Limited has announced the application for the quotation of 32,909,640 ordinary fully paid securities. This initiative follows transactions previously detailed in an Appendix 3B. The move indicates a proactive approach by the company to engage with the market effectively. The issued capital of the entity will reflect these changes following the successful quotation of the securities.
Read more →IMRNImmuron - FY25 global sales exceed projection, up 49% on prior year
Immuron Limited reported a significant sales increase for FY25, achieving A$7.3 million, a 49% rise compared to the previous year. The growth was driven by strong performance in both Australia and North America, with the latter seeing a remarkable 76% increase in sales. The company aims to continue expanding its market presence and consumer engagement in the upcoming fiscal year.
Read more →IMRNFY25 global sales exceed projection, up 49% on prior year Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sal
Immuron Limited reported a strong performance for FY25, with global sales of AUD$7.3 million, up 49% from the previous year. Notably, sales in North America surged by 76%, driven by effective marketing strategies and distribution improvements. The company's over-the-counter immune supplement, Travelan, continues to gain traction in the market, showcasing notable growth in Australia and the USA. Immuron plans to further invest in North America to sustain this upward trend in sales.
Read more →IMRNAppendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Wednesday
Immuron Limited has announced the application for quotation of a new issuance of 116,680 ordinary fully paid securities on the ASX, under the ticker IMC. This follows a previous announcement regarding a proposed placement, which is indicative of the company's ongoing capital raising efforts. The new securities will be quoted at an issue price of AUD 0.0708. The total number of fully paid securities on issue will increase to 233,959,013 post-quotation.
Read more →IMRNImmuron Letter to Shareholders: Projects Update
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has provided a project update highlighting its strong sales performance, expecting to exceed A$7 million this financial year. Key upcoming milestones include topline results for the Travelan clinical study anticipated in October 2025 and an IND submission for IMM-529 set for August 2025. Additionally, plans for launching ProIBS in Australia are in progress, with expected deliveries in 3Q2025 and a product launch slated for 1Q2026.
Read more →IMRNImmuron Travelan® highest sales in history
Immuron Limited has reported unprecedented sales growth for its product Travelan®, surpassing A$5 million for the first time. The company noted a 46% increase in global sales year-to-date, with significant contributions from both the USA and Canada. The December quarter saw record sales driven by a successful travel activation program and strong consumer demand ahead of peak travel seasons.
Read more →IMRNImmuron Travelan highest sales in history Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history March 2025 Quarter AUD$1.3 million up 2% on prior year Mar
Immuron Limited has reported record sales of AUD$5.3 million for its product Travelan in the fiscal year, representing a 46% increase year-over-year. Notably, the company achieved AUD$1.3 million in sales during the March 2025 quarter with substantial growth in North America, where sales increased by 86% year to date. The strong sales performance is attributed to effective marketing strategies and expanded pharmacy agreements, which have positioned Travelan favorably in the anti-diarrheal market.
Read more →IMRNImmuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
Immuron Limited has entered an exclusive distribution agreement to launch ProIBS® in Australia and New Zealand for treating Irritable Bowel Syndrome (IBS). The product, containing AVH200®, aims to improve digestive health and has shown high user satisfaction in studies. Immuron plans to leverage its established presence in the market to promote ProIBS® effectively.
Read more →IMRNImmuron Limited Appendix 4D Half-year report 1. Company details Name of entity: Immuron Limited ABN: 80 063 114 045 Reporting period: For the period ended 31 December 2024 Previous period: For the period ended 31 Decembe
Immuron Limited has released its Appendix 4D half-year report for the period ending December 31, 2024, showing a 69.6% increase in revenue but a 20% increase in losses. The company's ordinary activities resulted in a loss of A$2,488,819. Notably, sales of Travelan products have surged significantly, with plans for a pre-IND application for drug IMM-529 expected in the first half of 2025. Despite the revenue growth, the net tangible assets per share decreased sharply, and no dividends were declared for this period.
Read more →IMRNImmuron Travelan continued strong sales growth
Immuron Limited (NASDAQ: IMRN) reported continued strong sales growth of its over-the-counter immune supplement, Travelan®, with December 2024 Quarter sales reaching AUD $2.5 million, marking a 70% increase from the previous quarter and a 249% rise compared to the prior year. In Australia, sales surged 83% quarter-over-quarter while North American sales grew by 43%. The company's Chief Commercial Officer highlighted successful distribution expansions in both regions, contributing significantly to revenue performance. FY25 sales results are unaudited.
Read more →IMRNImmuron Travelan continued strong sales growth Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp December 2024 Half Year AUD$4.0 million up 70% on pcp Australia Decemb
Immuron Limited (NASDAQ: IMRN) reported strong sales growth for its immune supplement Travelan in the December 2024 quarter, with sales reaching AUD$2.5 million, marking a 70% increase from the previous quarter and a substantial 249% increase year-over-year. The company has achieved significant market penetration, particularly in Australia and North America, aided by expanded distribution agreements in pharmacy and grocery sectors. These preliminary sales figures indicate a robust demand for Travelan, which is intended to reduce the risk of travelers' diarrhea. The company's progress highlights its commitment to its growth strategy, although the figures are unaudited at this stage.
Read more →IMRNImmuron Announces New Research Collaboration targeting Antimicrobial Resistance
Immuron Limited has announced a research collaboration with Monash University aimed at tackling antimicrobial resistance through two primary proposals. One project will explore pathways that bacteria use to transfer DNA, while the second will focus on developing drugs against Vancomycin-resistant enterococci (VRE). The collaboration will utilize Immuron's technology platform, with initial activities supported by existing research budgets, enhancing potential for new therapeutic innovations. The global market for new antibiotics is expected to grow significantly, emphasizing the demand for solutions in this critical area.
Read more →IMRNImmuron Announces Travelan Clinical Trial Update
Immuron Limited has submitted the Clinical Study Report for its Phase 2 trial of Travelan® (IMM-124E) to the FDA, marking a significant step towards Phase 3. The trial, involving 776 subjects, demonstrated statistically significant improvements in immune response and gut microbiota compared to placebo. Key findings included lower antibody levels and faster clearance of ETEC bacteria, suggesting Travelan's potential efficacy in preventing travelers' diarrhea. Further research will explore the implications for gut health and microbiome dynamics.
Read more →IMRNImmuron Announces Travelan Clinical Trial Update Highlights: Travelan (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA Travelan (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology Results
Immuron Limited announced a successful Phase 2 clinical trial for Travelan (IMM-124E) and submitted the Clinical Study Report to the FDA, requesting an end of Phase 2 meeting. The trial demonstrated statistically significant immunology results, including lower levels of IgA and IgG in subjects treated with Travelan compared to placebo. Furthermore, Travelan improved gastrointestinal microbiota stability and diversity. These promising results may support its potential use in reducing the incidence of travelers' diarrhea.
Read more →IMRNAppendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 8/1/2025 The Proposed issue is: A placement or other type of issue
Immuron Limited has announced a proposed issue of 2,579,760 ordinary shares to be raised through placement. The funds will be utilized to support ongoing research and development activities as well as to provide working capital. This move highlights the company's effort to bolster its financial position and advance its business objectives.
Read more →IMRNAppendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name IMMURON LIMITED Date of this announcement Tuesday
Immuron Limited announced the issuance of 3,000,000 unquoted equity securities under its employee incentive scheme. These securities, specifically options expiring on various dates and priced at various exercise prices, are not intended to be listed on the Australian Securities Exchange (ASX). Additionally, details regarding key management personnel who are receiving these options have been provided. The announcement primarily focuses on compliance with ASX listing rules.
Read more →IMRNImmuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the Small Cap Growth Virtual Investor Conference on December 5, 2024. The presentation is aimed at individual and institutional investors, providing them an opportunity to engage in real-time Q&A. The company has reported impressive growth with a 172% increase in global sales, attributed largely to their product Travelan. Additionally, Immuron is planning further trials for its candidate drug IMM-529 after receiving positive feedback from the FDA.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
Immuron Limited's CEO, Steven Lydeamore, presented at the 21st Virtual Investor Summit Microcap Event. The company, which develops orally delivered targeted polyclonal antibodies, highlighted its flagship product Travelan®, an immunotherapy designed to prevent travelers' diarrhea. Additionally, Immuron is advancing its investigational drug IMM-529 for Clostridioides difficile infections, with promising preclinical results showcased. The presentation underscores Immuron's strategic focus on addressing significant infectious diseases through innovative therapies.
Read more →IMRNImmuron 2024 AGM Presentation Highlights: Global sales increased 172% in FY24 to $4.90m; Record Travelan sales of $4.86m Record monthly sales in October 2024 of $1.49m Completed and reported topline results for Travelan
Immuron Limited has reported significant financial growth for FY24, with global sales rising by 172% to $4.90 million, largely attributed to record sales of its product Travelan, which reached $4.86 million. The company also announced a record monthly sales figure of $1.49 million in October 2024. Additionally, Immuron successfully completed and reported topline results for Travelan, indicating positive progress in their business operations. This information was presented during the company's annual general meeting.
Read more →IMRNAppendix 3H - Notification of cessation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Thursday
Immuron Limited announced the cessation of 7,900,000 IMCAD options that expired on November 13, 2024, without being exercised. This announcement reflects a decrease in the company's securities and may impact investor sentiment negatively. The company’s current issued capital includes ordinary shares and performance rights, but the expiration of these options may indicate potential financial shortcomings or missed opportunities for growth. Following this development, shareholders could reassess their investment strategy concerning the company.
Read more →IMRNIMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2024 ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Date and Time of Meeting: Monday, 18 November 2024 at 11.00 am Place of Meeting: The Off
Immuron Limited has announced its 2024 Annual General Meeting scheduled for November 18, 2024, at 11:00 AM in Melbourne, Australia. Shareholders are encouraged to participate either in person or online, and the company has provided detailed instructions for voting. The meeting will include discussions on several key resolutions, including the adoption of the remuneration report and the re-election of directors. Importantly, additional information is included in the accompanying explanatory memorandum.
Read more →IMRNImmuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference
Immuron Limited's CEO, Steven Lydeamore, is set to participate in a fireside chat at the Maxim Virtual Healthcare Conference on October 16, 2024. The discussion will feature insights into the company's developments in biopharmaceuticals, particularly the oral polyclonal antibodies designed for infectious disease treatment. Immuron is known for its product Travelan, an immunotherapy that mitigates the risk of travelers' diarrhea, representing the company's commitment to innovative healthcare solutions. The presentation will be available on Immuron's corporate website for interested stakeholders.
Read more →IMRNImmuron Travelan continued strong sales growth Sales Highlights: Global September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia September 2024 Quarter AUD$1.0 million up 3% on prior quarter North America
Immuron Limited reported robust sales growth for its product Travelan in the September 2024 quarter, reaching AUD $1.5 million globally, a 13% increase from the previous quarter. Sales in North America surged by 48%, with additional expansion in Australia, where the product is now present in nine new pharmacy banner groups. The company emphasized its strong monthly sales on amazon.com in the U.S., adding to its overall positive performance. Travelan is marketed as an immune supplement targeting travelers' diarrhea, benefiting from its unique formulation.
Read more →IMRNNotice Under Section 708A(5) of the Corporations Act Melbourne, Australia
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has issued a notice under Section 708A(5) of the Corporations Act 2001. The notice includes details about the issuance of 1,147,083 ordinary shares dated October 7, 2024. This disclosure is part of compliance requirements under Australian corporate law.
Read more →IMRNNMRC Reports Results for Campylobacter Controlled Human Infection Model Study Melbourne, Australia
Immuron Limited has reported the interim results of a controlled human infection model study conducted by the US Naval Medical Research Command, focusing on a new oral therapeutic for Campylobacter and Enterotoxigenic Escherichia coli. The study demonstrated a 10.4% protective efficacy against moderate to severe campylobacteriosis, which is lower than previous results seen with the company's product, Travelan. Immuron plans to meet with the FDA regarding Travelan's progression to Phase 3 trials, with topline results from an associated clinical study anticipated in April 2025. Further data analysis from the NMRC is ongoing, and results will be presented at the upcoming International Workshop on Campylobacter, Helicobacter & Related Organisms.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia, September 26 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamor
Immuron Limited's CEO, Steven Lydeamore, provided a virtual presentation at the Emerging Growth Conference on September 26, 2024. He highlighted the company's focus on developing orally delivered targeted polyclonal antibodies for treating infectious diseases, particularly with their product Travelan. Travelan is designed to reduce the likelihood of travelers' diarrhea by utilizing hyper-immune bovine antibodies. Immuron's advancements in the development of these antibodies position the company favorably within the biopharmaceutical sector.
Read more →IMRNImmuron Limited Appendix 4E 30 June 2024 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2024 Name of entity: Immuron Limited ABN: 80 063 114 045 year ended: 30 June 2024 Previous period: 30 June
Immuron Limited announced its preliminary financial results for the year ended June 30, 2024, reporting a significant revenue increase of 171.7% to $4.9 million, mainly due to heightened sales of their product Travelan. However, the company also noted a substantial increase in net loss to approximately $6.9 million, attributed to higher research and development expenses. The results come alongside the completion of Phase 2 clinical trials for Travelan, demonstrating protective efficacy against travel-related diarrhea. Immuron is now planning future clinical trials and discussions with the U.S. FDA regarding its Phase 3 strategy.
Read more →IMRNImmuron Plans Phase 2 Trial for IMM-529 following FDA review
Immuron Limited announced it has received positive feedback from the FDA regarding its investigational drug IMM-529 for preventing and treating Clostridioides difficile infection (CDI). The company plans to file an investigational new drug application in the first half of 2025 and intends to initiate a Phase 2 clinical trial thereafter. IMM-529 is positioned as an adjunctive therapy to standard antibiotics, aiming to reduce reliance on antibiotics and improve patient outcomes. The drug has demonstrated promising pre-clinical results, which supports its potential in clinical settings.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation at Peak Biotech Showcase Melbourne, Australia, August 21 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will b
Immuron Limited (NASDAQ: IMRN) announced that CEO Steven Lydeamore will present at the Peak Biotech Showcase on August 21, 2024, in Melbourne, Australia. The company focuses on developing oral polyclonal antibodies for treating infectious diseases, with its flagship product, Travelan, designed to reduce the risk of travelers' diarrhea. This event highlights Immuron's ongoing commitment to innovation in the biopharmaceutical sector, showcasing its proprietary technology aimed at producing effective treatments for gastrointestinal disorders.
Read more →IMRNImmuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan
Immuron Limited announced the approval of a $3.5 million research award from the U.S. Department of Defense to advance the development of Travelan. This research will be conducted in collaboration with the Naval Medical Research Command and Walter Reed Army Institute of Research, focusing on an enhanced formulation targeting specific pathogens. The initiative aims to address the critical issue of infectious diarrhea, which significantly impacts the health and operational readiness of U.S. troops. The funding signals the confidence the Department of Defense has in Immuron's technology and its relevance to military health needs.
Read more →IMRNImmuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the Emerging Growth Conference on August 22, 2024. The presentation aims to engage investors and analysts through a real-time interactive format. Attendees will have the chance to submit questions in advance. This presentation highlights Immuron's focus on innovative therapies in the biopharmaceutical sector.
Read more →IMRNImmuron CEO, Steven Lydeamore webinar on MarketOpen Direct Connect Melbourne, Australia
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced that CEO Steven Lydeamore will host a webinar on MarketOpen Direct Connect on August 8, 2024. The webinar aims to engage with stakeholders and will also be available for free registration via Zoom. Immuron continues to focus on developing orally delivered targeted polyclonal antibodies, particularly for infectious diseases, including their product Travelan, which targets travelers' diarrhea. The company's research into IMM-529 demonstrates potential in treating recurrent Clostridioides difficile infections.
Read more →IMRNImmuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect
Immuron Limited (ASX: IMC; NASDAQ: IMRN) is hosting an investor webinar on August 8, 2024, led by CEO Steven Lydeamore. The webinar will focus on updates regarding the analysis from the Phase 2 trial of their product IMM-124E (Travelan®) and future steps regarding its development. Attendees will have the opportunity to ask questions in a live Q&A session following the presentation. This event signifies the company's commitment to transparent communication with its shareholders and demonstrates its ongoing efforts in addressing infectious diseases.
Read more →IMRNImmuron Travelan record sales globally, Australia and USA Sales Highlights: Global FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarte
Immuron Limited reported record sales of Travelan for FY 2024, reaching AUD $4.9 million globally, which reflects a significant 174% increase compared to the prior period. Notably, U.S. sales saw a remarkable growth of 74% for the full year, and a staggering 546% for the June 2024 quarter. The Australian market also contributed robustly with a 223% annual increase in sales. The company plans to further enhance brand awareness and distribution to sustain growth moving forward.
Read more →IMRNImmuron announces record Travelan sales globally, Australia and USA
Immuron Limited (NASDAQ: IMRN) reported record sales for its immune supplement Travelan®, achieving AUD $4.9 million in FY 2024, a 174% increase from the previous period. Australia saw sales growth of 223%, while the USA experienced a milestone with FY 2024 sales reaching AUD $1.1 million, a 74% increase. The June 2024 quarter also demonstrated robust performance with a 546% rise in USA sales. The company anticipates continued growth, particularly in North America, supported by increased brand investment and distribution efforts.
Read more →IMRNImmuron CEO, Steven Lydeamore to present at Sharewise Melbourne, Australia
Immuron Limited announced that its Chief Executive Officer, Steven Lydeamore, will present at the Sharewise event on July 9, 2024, in Melbourne, Australia. The company, known for its development of orally delivered targeted polyclonal antibodies, aims to provide solutions for infectious diseases such as travelers' diarrhea. The announcement highlights Immuron's ongoing commitment to innovation and growth in the biopharmaceutical sector.
Read more →IMRNIMM-529 pre-IND FDA filing Melbourne, Australia
Immuron Limited has announced the filing of a pre-IND application for its therapeutic candidate IMM-529 with the FDA. This move aims to progress towards Phase 2 clinical studies to address the urgent healthcare challenge posed by recurrent Clostridioides difficile infections (CDI). Early pre-clinical data indicate promising results against CDI, showcasing IMM-529's potential to act as an adjunctive therapy. The company’s collaboration with Monash University and findings suggest significant market opportunity should the drug prove effective.
Read more →IMRNImmuron requests pre-IND meeting for IMM-529 with FDA filing
Immuron Limited has filed a pre-IND application with the FDA for IMM-529, targeting the treatment and prevention of recurrent Clostridioides difficile infections (CDI). The drug aims to address the pressing health concern of CDI, which affects over 400,000 people annually in the U.S. The company plans to advance to Phase 2 clinical studies and has collaborated with Monash University to develop its treatment approach. If successful, IMM-529 has the potential for significant market revenue based on current estimates.
Read more →IMRNAppendix 3Z Final Director's Interest Notice Rule 3.19A.3 Appendix 3Z Final Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given
Immuron Limited has submitted a Final Director's Interest Notice to the ASX, complying with listing rule 3.19A.3. The notice details information regarding director Roger Aston, including his cessation as a director effective May 31, 2024. The document specifies that any relevant information not available now must be reported to the ASX as it becomes available. The notice does not disclose significant interests or investments that could impact the company's outlook.
Read more →IMRNImmuron CEO Steven Lydeamore to present at Peak Sky High
Immuron Limited announced that CEO Steven Lydeamore will present at the Peak Sky High luncheon organized by Peak Asset Management on June 1, 2024. This event is expected to provide an opportunity to discuss the company’s advancements in developing orally delivered targeted polyclonal antibodies, specifically for treating infectious diseases such as travelers' diarrhea. The presentation will include insights on the company’s product, Travelan®, which is currently available in Australia, Canada, and the U.S. and aims to protect against digestive tract infections.
Read more →IMRNImmuron Board Changes
Immuron Limited has announced the resignation of Dr. Roger Aston from his role as Non-Executive Director, effective immediately. Dr. Aston, who contributed significantly to the company's growth over 12 years, was pivotal during challenging times, including the COVID pandemic. The company also welcomed Dr. Jeannie Joughin as a new Non-Executive Director, effective June 1, 2024, who brings considerable industry experience and expertise. Immuron continues to advance its scientific and commercial efforts, focusing on its unique hyper-immune colostrum applications.
Read more →IMRNImmuron Limited Appendix 4D Half-year 31 December 2023 Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2023 Previous period: 31 December 2022 Results for announcement to the market $ Reve
Immuron Limited has reported significant revenue growth for the half-year ending December 31, 2023, with revenues up 303.6% compared to the previous period. However, the company also noted an increased net loss of A$2,073,182, reflecting ongoing financial challenges. The completion of key clinical trials for its products, including Travelan, may enhance its future profitability and market positioning. The report further details the company's financial status and performance metrics against previous periods.
Read more →IMRNImmuron Limited to Present at the Emerging Growth Conference
Immuron Limited (NASDAQ: IMRN) will present at the Emerging Growth Conference on May 8, 2024. The interactive online event aims to connect individual and institutional investors with the company's CEO, Steven Lydeamore, who will present and answer questions. The presentation is scheduled for 4:25 PM Eastern time and will be archived for those unable to attend live. This conference provides a platform for Immuron to communicate its developments to a broad audience.
Read more →IMRNImmuron Director Resignation
Stephen Anastasiou has resigned from his role as Non-Executive Director of Immuron Limited, effective immediately. A board member since 2013, he decided to retire in order to focus on personal interests and family commitments. During his tenure, Immuron launched significant products and is experiencing growth and opportunity. His departure may affect continuity within the board, but the company retains hope for future success.
Read more →IMRNBoard Change Melbourne, Australia
Stephen Anastasiou has resigned from his position as Non-Executive Director of Immuron Limited to focus on personal interests and business commitments. His resignation marks the end of a tenure that began in 2013, during which he helped guide the company through significant developments, including the launch of Travelan in North America. The management appreciates his contributions and expresses best wishes for his future endeavors as Immuron looks forward to new growth opportunities.
Read more →IMRNImmuron CEO, Steven Lydeamore to present at The Watchlist Melbourne, Australia, April 23 , 2024 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is plea
Immuron Limited announced that its CEO, Steven Lydeamore, will present at The Watchlist event in Melbourne on April 23, 2024. The presentation will cover updates on Travelan's sales growth and the company's clinical research progress. Following the presentation, there will be a moderated Q&A session, allowing attendees to interact directly with the CEO. This event reflects Immuron's ongoing commitment to keeping stakeholders informed about its developments and milestones.
Read more →IMRNImmuron to host Live Virtual Event
Immuron Limited (ASX:IMC; NASDAQ:IMRN) announced plans to host a Live Virtual Event on April 30, 2024, led by CEO Steven Lydeamore and other key executives. The event will discuss positive interim results from a Phase 2 trial of its product Travelan, which has shown significant efficacy in preventing ETEC-induced traveler’s diarrhea. Immuron aims to transition to Phase 3 trials following a successful outcome, underpinned by funding from the US Department of Defense and a promising market projection for the product. Investors and stakeholders are invited to gain insights into the company's future developments.
Read more →IMRNImmuron to host Live Virtual Event Melbourne, Australia
Immuron Limited will host a Live Virtual Event on April 30, 2024, to discuss the positive results from its Phase 2 clinical trial of Travelan and the upcoming Phase 3 trial. The trial demonstrated substantial efficacy in reducing travelers' diarrhea caused by ETEC, showcasing a 36.4% reduction in severe cases compared to a placebo. The event aims to inform shareholders and potential investors about the company's advancements and proprietary technology in oral immunotherapeutics. Immuron's progress sets it on a path to join an exclusive group of biotechs entering Phase 3 trials.
Read more →IMRNImmuron Travelan sales continued strong growth Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Austr
Immuron Limited reported strong financial results for its immune supplement, Travelan, with global sales rising to AUD $3.6 million for the fiscal year to March 2024, representing a 154% increase compared to the prior period. The Australian sales also showcased impressive growth, with an increase of 234%, while the U.S. sales began through Walmart.com. Chief Commercial Officer expressed optimism for continued growth, particularly with increased marketing investment focused on peak travel seasons in North America.
Read more →IMRNImmuron Travelan sales continued strong growth
Immuron Limited reported strong financial results for Travelan sales, with a 154% increase year-to-date to AUD $3.6 million compared to the prior year period. The sales in Australia surged by 234%, and the company has recently begun selling Travelan in the USA through Walmart.com. The positive growth trend is attributed to increased consumer awareness and anticipated further expansion during the peak vacation periods. The company is optimistic about replicating its Australian success in North America.
Read more →IMRNImmuron CEO, Steven Lydeamore to present at Coffee Microcaps Melbourne, Australia, March 14 , 2024 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is p
Immuron Limited (NASDAQ: IMRN) announced that its CEO, Steven Lydeamore, will present at the Coffee Microcaps conference on March 14, 2024, in Sydney, Australia. The company specializes in developing and commercializing targeted polyclonal antibodies for infectious diseases. Notably, their product Travelan is a preventive therapy for travelers' diarrhea, supported by existing licenses in Australia, Canada, and the U.S. This presentation may aim to attract potential investors and promote Immuron's innovative approaches to managing infectious diseases.
Read more →IMRNImmuron Announces Positive Results Support Travelan progress to Phase 3 Clinical Trials in the US
Immuron Limited has announced positive interim results for Travelan®, confirming its efficacy in preventing moderate to severe diarrhea caused by the ETEC pathogen. The Phase 2 data indicates a significant protective effect, leading the company to seek FDA guidance for Phase 3 clinical trials. Despite lower than expected attack rates in the study, Travelan® has shown substantial efficacy compared to placebo. This progress is bolstered by financial support from the U.S. Department of Defense, demonstrating the potential military applications of the treatment.
Read more →IMRNPositive Results Support Travelan progress to Phase 3 Clinical Trials in the US Highlights: Immuron proceeding to Phase 3 registration strategy with the FDA Travelan topline clinical trial results demonstrate protective
Immuron Limited (NASDAQ: IMRN) announced positive interim topline results for Travelan, which demonstrated efficacy in preventing moderate to severe diarrhea caused by enterotoxigenic Escherichia coli (ETEC). The Phase 2 study involved 60 participants and showed that a single daily dose of 1200 mg of Travelan was beneficial. These results enabled Immuron to progress to Phase 3 clinical trials with the FDA to assess the drug's potential as a prophylactic measure for travelers' diarrhea. The study, funded by the U.S. Department of Defense, aims to support military personnel visiting regions with high infection risk.
Read more →IMRNMarket Announcement 5 March 2024 Immuron Limited (ASX: IMC) - Trading Halt Description The securities of Immuron Limited ( IMC') will be placed in trading halt at the request of IMC, pending it releasing an announcement.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has requested a trading halt pending the announcement of top-line results from its Phase 2 IMM-124E clinical trial. According to ASX Listing Rule 17.1, this halt will remain in effect until the announcement is made or normal trading resumes on March 7, 2024. The company has indicated that it is not aware of any issues that would prevent the halt from being granted.
Read more →IMRNImmuron Presentation Australian Biologics Festival 2024
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced that their Research & Development Manager, Joanne Casey, PhD, will present at the Australian Biologics Festival 2024 in Melbourne, Australia. This event highlights the company's commitment to sharing advancements in biopharmaceuticals. The presentation slide deck will be available on their website. Immuron focuses on developing orally delivered targeted polyclonal antibodies for infectious diseases.
Read more →IMRNAustralian Biologics Festival 2024 Melbourne, Australia
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced that their Research & Development Manager, Joanne Casey, PhD, will present at the Australian Biologics Festival 2024 in Melbourne on February 21, 2024. The presentation will likely highlight the company’s orally administered immunotherapy product, Travelan, which helps prevent traveler's diarrhoea and related gastrointestinal disorders. Immuron focuses on developing and commercializing targeted polyclonal antibodies for infectious diseases. The company is also building strategic collaborations in the US market to enhance product reach and effectiveness.
Read more →IMRNImmuron achieves record Travelan sales
Immuron Limited has announced record sales of its over-the-counter immune supplement, Travelan, reaching $2.7 million in year-to-date January 2024, surpassing the peak sales of the full year 2020. Australian sales accounted for $2.1 million, marking a significant increase compared to the previous year's performance. The company has also resumed sales in Canada through McKesson, anticipating similar growth as it increases brand awareness and distribution in North America during peak travel seasons. The surge in sales reflects rising international travel and an investment in marketing.
Read more →IMRNImmuron achieves record Travelan sales Highlights: Travelan sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 million Australian Travelan YTD Jan 2024 sales $2.1 million USA Travelan YTD Jan 202
Immuron Limited announced record sales of its over-the-counter immune supplement, Travelan, with year-to-date sales of AUD $2.7 million as of January 2024, surpassing previous peak sales figures. The Australian market saw a notable increase in sales, rising to AUD $2.1 million compared to AUD $0.3 million the prior year. The company is optimistic about expanding market presence in North America, especially as travel activities are expected to rise in the upcoming spring and summer seasons. Travelan serves as a prophylactic treatment against travelers' diarrhea, a concern for international travelers.
Read more →IMRNInvestor Webinar Presentation Melbourne, Australia
Immuron Limited announced that CEO Steven Lydeamore will present at an investor function in Sydney, Australia, on February 8, 2024. The presentation will highlight the company's product, Travelan, which helps prevent traveler's diarrhoea through orally administered passive immunotherapy. Travelan is already approved in Australia and Canada and is marketed as a dietary supplement in the U.S. Immuron focuses on developing targeted polyclonal antibodies for treating infectious diseases.
Read more →IMRNImmuron CEO, Steven Lydeamore Investor Webinar Presentation
Immuron Limited has announced that its CEO, Steven Lydeamore, will present at the Monsoon Communications Investor function in Sydney on February 8, 2024. This event is an opportunity to engage with investors and share company developments. Furthermore, the slide deck for the presentation will be accessible on the company's website, promoting transparency and communication. Immuron is focused on developing targeted polyclonal antibodies for infectious diseases.
Read more →IMRNImmuron achieves record half yearly Travelan sales
Immuron Limited reported record sales for its gastrointestinal health supplement Travelan, with half yearly sales amounting to AUD $1,853,048 for H1, FY24. This reflects a significant increase of 132% compared to pre-pandemic sales in H1, FY20, and a considerable improvement from AUD $260,205 in H1, FY23. The company's sales growth is supported by the resumption of international travel and a successful launch on Amazon, with expectations for continued growth as travel peaks in spring and summer. Sales from Travelan have shown promising trends, indicating a strong market demand for the product.
Read more →IMRNImmuron Clinical Trials Update
Immuron Limited has announced significant progress in its clinical development portfolio, including the completion of the inpatient phase for its campylobacter challenge study and the manufacturing of its IMM-529 drug substance targeting Clostridioides Difficile. The company is preparing for a Pre-IND submission to the FDA in the first half of 2024. Additionally, the Travelan clinical study has also completed its inpatient stage, with results expected in mid-2024. Immuron is actively collaborating with research organizations for further testing and development of its therapeutic candidates.
Read more →IMRNImmuron Clinical Trials Update Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information packa
Immuron Limited has provided an update on its clinical development portfolio, highlighting the completion of the inpatient phase of its campylobacter clinical study led by Johns Hopkins University. The company has also successfully manufactured drug substance IMM-529, which targets Clostridioides Difficile, and plans to submit a Pre-IND package to the FDA in the first half of 2024. Additionally, the Travelan clinical study's inpatient phase has been completed, with follow-up visits scheduled for later in 2024. Overall, these developments mark significant progress in Immuron's clinical programs.
Read more →IMRNImmuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
Immuron Limited has announced the enrollment of the first participants in a clinical trial evaluating their new therapy, CampETEC, targeting Campylobacter and ETEC infections. This study, conducted in collaboration with the US Naval Medical Research Command, seeks to assess the product's efficacy in preventing moderate to severe diarrhea. The trial, led by Dr. Kawsar Talaat at Johns Hopkins University, will begin the in-patient stage, aiming for completion by December 2023. Results are expected to be reported in the latter half of 2024.
Read more →IMRNConstitution of Immuron Limited ACN 063 114 045 [Amended at a Meeting of Shareholders held on Tuesday 21 November 2023] Table of Contents 1. Definitions and interpretation 1 1.1 Definitions 1 1.2 Interpretation 2 1.3 Rep
The recent meeting of shareholders for Immuron Limited resulted in amendments to the company's constitution. This detailed document outlines various governance aspects including the powers of directors, capital structure, and share management. Changes were recorded to comply with relevant legal requirements and regulations, ensuring the company adheres to best practices in corporate governance. The constitution remains subject to the Listing Rules of the ASX contingent upon the company's listed status.
Read more →IMRNAGM PRESENTATION 21 NOVEMBER , 2023 NASDAQ: IMRN ASX: IMC Steven Lydeamore - CEO 2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron's current expectations, estimate
Immuron Ltd presented at its AGM on November 21, 2023, outlining promising financial results and growth in sales. Notably, the company reported a 136% increase in global sales for FY23, driven primarily by its Travelan product, which has become a leading option in Australia's Antidiarrheal category. The presentation highlighted ongoing advancements in clinical programs with several near-term milestones anticipated. Immuron aims to expand its market presence and product offerings in various geographies.
Read more →IMRNImmuron CEO Steven Lydeamore Investor Webinar Presentation
Immuron Limited is hosting an investor webinar on November 14, 2023, led by CEO Steven Lydeamore. During the session, he will discuss the company's business updates and upcoming milestones. Shareholders will have a chance to participate in a moderated Q&A after the presentation. A recording will be made available on the company’s website after the event.
Read more →IMRNImmuron CEO, Steven Lydeamore to present at AusBioInvest Melbourne, Australia
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the AusBioInvest conference in Melbourne, Australia, on October 30, 2023. The presentation will cover the company's advances in its immunotherapy product, Travelan, which aims to reduce the risk of traveler's diarrhoea. Travelan operates by using hyperimmune bovine antibodies to combat diarrhoea-causing bacteria. The event aligns with growing travel post-COVID pandemic, which could positively impact demand for Travelan products.
Read more →IMRNImmuron CEO Steven Lydeamore presented at AusBioInvest
Immuron Limited announced that its CEO, Steven Lydeamore, presented at the AusBioInvest 2023 event on October 30th. The presentation detailed the company's strategies and developments in the biopharmaceutical sector. Immuron is focused on developing orally delivered targeted polyclonal antibodies to treat infectious diseases. The company has made the presentation available on its website for public access.
Read more →IMRNIMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2023 ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Date and Time of Meeting: 21 November 2023 at 10.00 am Place of Meeting: The Offices of
Immuron Limited is holding its Annual General Meeting on November 21, 2023, at the offices of K & L Gates in Melbourne. The meeting will address several important resolutions, including the re-election of director Dr. Roger Aston and approval of an increased capacity for issuing equity securities. Shareholders can attend in person or register for an online webcast. Proxy voting is encouraged for those unable to attend.
Read more →IMRNTravelan Clinical Study Cohort 2 commences Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan Clinical Trial Clinical Trial to examine a dosing regimen for Travelan more suited to the US military
Immuron Limited has commenced the second cohort of its clinical trial for Travelan, enrolling 34 healthy volunteers to evaluate the treatment's efficacy against infectious diarrhea caused by ETEC. The study, led by Dr. Mohamed Al-Ibrahim, aims to assess Travelan's safety and effectiveness compared to a placebo. The trial's results are expected to be reported in June 2024, which may significantly impact preventive treatments for conditions affecting travelers and military personnel. As antibiotic resistance increases, Travelan presents a promising alternative in managing travel-related gastrointestinal illnesses.
Read more →IMRNImmuron Announces Travelan Clinical Study Cohort 2 commences
Immuron Limited announced the commencement of the second cohort in its Travelan® clinical trial, involving 34 healthy volunteers. This phase aims to evaluate a new dosing regimen suitable for the U.S. military against enterotoxigenic Escherichia coli (ETEC) to prevent traveler's diarrhea. The first cohort was completed in August 2023, and follow-up from both groups is expected to conclude by April 2024. Results from this study will be in the focus of findings anticipated to release in June 2024.
Read more →IMRNImmuron achieves record quarterly Travelan sales Highlights: Record quarterly Travelan sales of $1,550,240 Total sales of A$1,565,767 in Q1, FY24 o $1,508,933 increase on Q1, FY23 sales o 130% higher than pre-pandemic pe
Immuron Limited announced record quarterly sales of its Travelan product, reaching AUD $1,550,240 in Q1 FY24. This marks a significant increase of 236% compared to pre-pandemic levels and demonstrates strong demand post-GMP clearance from authorities. The sales performance is bolstered by rising traveler numbers approaching pre-pandemic statistics, and Immuron expects continued growth as consumers increasingly purchase the product through pharmacies. The company has also seen positive sales trends from its Amazon launch in the United States.
Read more →IMRNImmuron achieves record quarterly Travelan sales
Immuron Limited reported record quarterly sales of its gastrointestinal supplement Travelan, reaching AUD $1,550,240 in Q1 FY24, a significant increase of 236% compared to the pre-pandemic period in Q1 FY20. The sales growth is attributed to improved supply following a resolution of previous stock outages and increased travel activity. Anticipating continued demand, Immuron is well-positioned for further sales growth as consumer travel resumes, especially with favorable statistics indicating a rise in short-term resident returns and international travel departures in 2023.
Read more →IMRNImmuron CEO, Steven Lydeamore to present at LD Micro Melbourne, Australia, October 4 , 2023 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is pleased
Immuron Limited (NASDAQ: IMRN; ASX: IMC) announced that its CEO, Steven Lydeamore, will present at the 16th annual LD Micro Main Event on October 4, 2023. The presentation aims to provide insights into the company's growth and development, particularly around their flagship product, Travelan, which has seen record sales as travel increases post-COVID. Immuron is focusing on expanding its market reach and enhancing its product offerings in the coming fiscal year.
Read more →IMRNCorporate Governance Immuron Limited and its Board of Directors are committed to implementing and achieving an effective corporate governance framework. Our Corporate Governance Statement can be found on our website at w
Immuron Limited has reported a successful fiscal year 2023 with notable sales growth for its oral immunotherapeutic product Travelan in both Australia and North America. Sales increased by 136% globally, showcasing a rebound from pre-pandemic levels as travel resumes. The company received FDA approval for its Investigational New Drug applications for Travelan and a new Campylobacter ETEC therapeutic, indicating promising advancements in their clinical development efforts. Additionally, Immuron has secured a European patent related to treatments for Clostridium difficile infections, strengthening its market position.
Read more →IMRNImmuron achieves record monthly Travelan sales
Immuron Limited reported a record monthly sales figure of A$1.18 million for its gastrointestinal supplement Travelan in August 2023, representing a 7984% increase from August 2022 sales. This sales surge follows the resolution of previous stock outages due to regulatory clearance. The company expects ongoing demand as pharmacies restock to meet consumer needs, and recent sales through Amazon have outperformed traditional B2B channels. The rise is also linked to a rebound in travel trends among residents, signaling a potential for continued growth in sales as demand increases during peak travel seasons.
Read more →IMRNImmuron achieves record monthly Travelan sales Highlights: Record monthly Travelan sales Australian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) Melbourne, Australia
Immuron Limited announced record monthly sales for its gastrointestinal health supplement, Travelan, achieving AUD $1.18 million in August 2023, a significant increase of 7984% from the previous year. This surge is attributed to the resolution of previous stock outages following the receipt of GMP Clearance from the Therapeutic Goods Administration. The company anticipates ongoing demand as retail pharmacies continue to sell Travelan to consumers, especially with sales on platforms like Amazon surpassing earlier projections. Overall, the company is optimistic about sustained growth as travel regains momentum.
Read more →IMRNImmuron CEO, Steven Lydeamore to present at H.C. Wainwright
Immuron Limited announced that its CEO, Steven Lydeamore, will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th. The presentation aims to highlight the company's developments in developing orally delivered targeted polyclonal antibodies for infectious diseases. An available webcast will provide interested parties access to the presentation. Immuron is an Australian biopharmaceutical firm listed on both the ASX and NASDAQ.
Read more →IMRNImmuron Limited Appendix 4E 30 June 2023 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2023 Name of entity: ABN: Year ended: Previous period: Immuron Limited 80 063 114 045 30 June 2023 30 June
Immuron Limited has released its preliminary financial report for the year ending June 30, 2023, reporting a 135.8% increase in revenue from ordinary activities. However, the company reported an increased net loss of $3,786,507, up from $2,854,254 in the previous year. The rise in losses is attributed to escalated research and development expenses as the company resumed activities following COVID-19 delays. Despite the losses, there are optimistic projections for revenue growth from the Travelan product.
Read more →IMRNImmuron to present at the Military Health System Research Symposium
Immuron Limited (NASDAQ: IMRN) is set to present at the Military Health System Research Symposium in Kissimmee, Florida from August 14 to 17, 2023. The company will exhibit and showcase two posters, focusing on treatments for travelers' diarrhea among military personnel. This event allows Immuron to engage with a wide audience of healthcare professionals and researchers from the U.S. Department of Defense. With the increasing challenges of antibiotic resistance, the company's innovative solutions aim to address critical health needs in the military.
Read more →IMRNImmuron Receives TGA GMP Clearance Highlights: Immuron Receives TGA GMP Clearance Immuron to release and dispatch Travelan to customers this week Melbourne, Australia
Immuron Limited has received GMP Clearance from the Therapeutic Goods Administration (TGA) for its packaging supplier, allowing the release of Travelan for sale in Australia. This follows a significant sales increase of 136% in FY23 compared to FY22. The company intends to dispatch Travelan to customers shortly, thereby resolving previous stock shortages. Immuron is optimistic about continued sales growth, aided by recent expansion efforts, including the launch of an Amazon storefront in the USA.
Read more →IMRNImmuron Announces First Patients Enrolled in Travelan Clinical Study
Immuron Limited has announced that the first cohort of 30 healthy volunteers has been enrolled in the Travelan clinical trial, intended to assess a more suited dosing regimen for the US military. This Phase 2 study is investigating the efficacy of Travelan in preventing infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC). The study is being conducted at the Pharmaron CPC FDA inspected facility in Maryland, with results expected in the first half of 2024. Additional trials are being conducted by the U.S. Department of Defense with further patient enrollment anticipated through 2024.
Read more →IMRNImmuron CEO, Steven Lydeamore to present at Bioshares
Steven Lydeamore, the CEO of Immuron Limited, is set to present at the 17th Bioshares Biotech Summit in Hobart, Australia on July 24, 2023. The event emphasizes Immuron's efforts in the biopharmaceutical sector, focusing on the development of orally delivered targeted polyclonal antibodies. A copy of the presentation slide deck has been made available on the company's website, enhancing transparency for stakeholders. The participation in this summit signifies an opportunity for Immuron to engage with the biotech community and showcase its advancements.
Read more →IMRNLetter to Shareholders Highlights: Ateria has launched Juvia containing breakthrough natural ingredient ERME in Australia New clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to
Immuron Limited has announced the launch of Juvia, a supplement aimed at individuals suffering from irritable bowel syndrome (IBS), in Australia. This product, which contains the natural ingredient ERME, has already been successful in the UK with positive consumer testimonials and growing sales. A new clinical study is also underway with the NHS in Swansea, Wales, targeting IBS caused by carbohydrate malfermentation. The company is optimistic about its Australian launch, supported by robust marketing strategies.
Read more →IMRNImmuron Business Update - Ateria Health launches Juvia™ in Australia
Immuron Limited announced that Ateria Health has launched Juvia™, a new product aimed at treating irritable bowel syndrome (IBS), in Australia. This launch follows successful sales in the UK and is supported by a positive consumer reception. Additionally, a new clinical study is being conducted in Swansea, Wales, evaluating ERME™, the natural ingredient in Juvia™, which has shown beneficial effects on gut health in previous studies. Immuron is also working on regulatory strategies for Juvia™'s broader distribution in Australia, including pharmacy sales.
Read more →IMRNImmuron FY23 Sales increase 136% on FY22 Sales Highlights: Australian FY23 sales of A$1.16 M (478% increase on FY22 sales) USA FY23 Travelan sales of A$643 k (28% increase on FY22 sales) Global FY23 sales of A$1.80 M (13
Immuron Limited reported a remarkable 136% increase in FY23 sales, achieving AUD $1.80 million, compared to AUD $765k in FY22. The company noted significant growth in Australian sales, with Travelan and Protectyn generating AUD $1.16 million, representing a 478% increase from the previous year. Despite this success, the company has faced challenges, including short-term stock outages and ongoing delays in securing GMP Clearance from the Therapeutic Goods Administration. Nonetheless, Immuron is poised for further growth, with sufficient inventory to meet current demands and potential expansion into new markets.
Read more →IMRNImmuron FY23 Sales increase 136% on FY22 Sales
Immuron Limited reported significant sales growth for FY23, with global sales reaching A$1.80 million, a 136% increase over FY22. Australian sales alone surged by 478%, driven by rebound in overseas travel. However, the company faces challenges with potential stock outages linked to increased demand and delays in obtaining GMP Clearance from the Therapeutic Goods Administration, which is currently affecting inventory release. Despite these hurdles, Immuron remains focused on expanding its market presence and product portfolio.
Read more →IMRNImmuron Chairman Transition Melbourne, Australia
Immuron Limited announced the transition of Paul Brennan from Non-Executive Director to Chairman, effective July 1, 2023. This leadership change follows the company's FDA approvals for two Investigational New Drug Applications. Dr. Roger Aston will move to a Non-Executive Director role, continuing to provide guidance as the company progresses with its Phase 2 trials. The company anticipates significant milestones, including a clinical trial completion and an IND submission for IMM-529, signaling a strategic drive for growth in the coming year.
Read more →IMRNImmuron Chairman Transition
Immuron Limited has announced the transition of Paul Brennan from Non-Executive Director to Chairman, effective July 1, 2023. This change marks a critical leadership shift following the FDA's approval of two Investigational New Drug Applications. Brennan intends to guide the company through its next phase of growth, which includes completing clinical trials and expanding market presence. The company is also focused on further developing its proprietary technology platform for treating infectious diseases.
Read more →IMRNLetter to Shareholders Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission Recruitment and screening update for Travelan Controlled Human Infection Model (CHIM) Clinic
Immuron Limited has announced the approval to proceed with the cGMP manufacturing of IMM-529 and to move forward with its FDA pre-IND submission. The company received favorable feedback from experts regarding IMM-529's mechanism in targeting Clostridioides difficile infections. Additionally, recruitment for the Travelan controlled human infection model clinical trial has begun, with screening of candidates set to start on June 28, 2023. The Phase II trial aims to assess the safety and efficacy of Travelan compared to a placebo in healthy participants.
Read more →IMRNImmuron Business Update: Letter to Shareholders
Immuron Limited (IMRN) announced advancements in its product pipeline, including the approval for cGMP manufacturing of IMM-529 and plans for an FDA pre-IND submission. IMM-529 targets Clostridioides difficile (C. difficile) infection, a serious gastrointestinal disease. The company also reported progress in its Travelan clinical trial, having selected candidates for in-person screening in Baltimore. These developments suggest a promising outlook for both products in addressing significant health issues.
Read more →IMRNImmuron CEO, Steven Lydeamore presents at LD Micro Melbourne, Australia
Immuron Limited, an Australian biopharmaceutical company, announced that CEO Steven Lydeamore presented at the LD Micro Invitational XIII conference in Los Angeles. The presentation highlighted the company's flagship product, Travelan, which is witnessing strong sales and may see challenges due to stock shortages. Immuron is also exploring opportunities to expand its market reach into Asia and Europe, indicating a proactive approach to growth in the biopharmaceutical space.
Read more →IMRNImmuron Initiates Recruitment of Travelan Clinical Study
Immuron Limited has commenced recruitment for a clinical study utilizing Travelan to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli. The study received necessary approvals from the U.S. Army Medical Research and Development Command and will evaluate the efficacy of Travelan in a controlled human infection model. Up to 60 healthy participants are expected to be recruited, with headline results anticipated in the first half of 2024. This trial is one of several studies focused on developing treatments for travel-related illnesses.
Read more →IMRNImmuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
Immuron Limited has announced that the U.S. FDA has lifted the clinical hold on its Investigational New Drug (IND) application for a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC). This approval allows for two Phase 2 clinical trials to evaluate the efficacy of the product in preventing infectious diarrhea caused by these pathogens. The trials will take place at the Johns Hopkins University Center for Immunization Research and involve 60 healthy volunteers. The development is particularly significant for addressing health issues faced by travelers and military personnel.
Read more →IMRNImmuron CEO, Steven Lydeamore to present at Coffee Microcaps
Immuron Limited (ASX: IMC; NASDAQ: IMRN) is set to have its CEO, Steven Lydeamore, present at the Coffee Microcaps Conference in Melbourne. The company is recognized for its development of oral immunotherapeutics, particularly the Travelan® product, which aims to mitigate travelers' diarrhea. This presentation aims to spotlight the company's achievements and its commitment to addressing gut-mediated diseases.
Read more →IMRNImmuron Q3 FY23 Business Update Presentation
Immuron Limited has provided a business update for Q3 FY23, reporting worldwide sales of A$320,000 for the first two weeks of April 2023. This sales figure contributes to a total revenue of A$875,000 for the entire quarter. The year-to-date sales have shown a remarkable increase of 233% compared to the same period last year, amounting to A$1,779,000. The company is inviting investors to join a webcast hosted by CEO Steven Lydeamore to discuss these updates further.
Read more →IMRNQ3 FY23 Business Update Presentation Melbourne, Australia
Immuron Limited (ASX: IMC; NASDAQ: IMRN) recently presented its Q3 FY23 business update, showcasing significant revenue growth and operational advancements. The company reported a year-to-date revenue increase of 233%, with strong sales from both Australian and international markets. Key developments include the completion of toxicology studies and recruitment for clinical trials, including a notable recruitment rate for its IMM-124E clinical trial. Immuron is also assessing expansion opportunities into Asian and European markets while ensuring adequate supply for current sales.
Read more →IMRNImmuron Q3 Sales reach 150% of 1H Sales
Immuron Limited reported a significant increase in its sales for the third quarter of FY23, achieving A$577,000 in Australia and A$298,000 in North America. This resulted in a global year-to-date sales total of A$1.46 million, representing a 239% increase from the same period in FY22. The growth in sales is attributed to a rebound in overseas travel and an increase in distribution through travel clinics. Immuron continues to focus on expanding its sales and product portfolio.
Read more →IMRNImmuron Q3 Sales reach 150% of 1H Sales Highlights: Australian Q3 FY23 sales of A$577 k (201% of 1H sales) North American Q3 FY23 Travelan sales of A$298 k (100% of 1H sales) Global Q3 YTD FY23 sales of A$1.46 M represen
Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported a substantial increase in sales for Q3 FY23, with total sales reaching AUD $1.46 million, a 239% rise compared to the same period in FY22. Sales for its over-the-counter products, Travelan and Protectyn, were particularly strong, driven by a rebound in overseas travel and increased demand. The company's sales in North America also showed growth, with Q3 sales matching those of the first half of FY23. Immuron continues to focus on its growth strategy and the expansion of its product portfolio.
Read more →IMRNINVESTOR PRESENTATION BUSINESS UPDATE 28 FEBRUARY, 2023 NASDAQ: IMRN ASX: IMC Steven Lydeamore - CEO 2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron's current ex
Immuron Ltd (NASDAQ: IMRN, ASX: IMC) provided a business update highlighting strong revenue growth for the fiscal year-to-date 2023, reporting a 234% increase compared to the previous year. The company resolved supply chain challenges for its flagship product, Travelan, now widely available again. The firm plans to explore international market expansions and has a strong financial position, with $18.5 million in cash. However, future projections are subject to risks and uncertainties inherent in product development and commercialization.
Read more →IMRNImmuron Limited Appendix 4D Half-year 31 December 2022 Name of entity: Immuron Limited ABN: Half-year ended: Previous period: 80 063 114 045 31 December 2022 31 December 2021 Results for announcement to the market $ Reve
Immuron Limited has reported encouraging financial results for the half-year ended December 31, 2022, marked by a substantial increase in revenue of 152.7% to $583,646. Despite a net loss after tax that rose by 9.2% to $1,978,383, the company achieved FDA approval to initiate a clinical trial for Travelan, its product aimed at preventing infectious diarrhea. Additionally, a European Patent has been secured for a method to treat Clostridium difficile, enhancing its position in the market. Overall, the company continues its development efforts while facing challenges related to profitability.
Read more →IMRNImmuron CEO, Steven Lydeamore to host an investor webinar
Immuron Limited, an Australian biopharmaceutical company, has announced that its CEO, Steven Lydeamore, will host a live webcast for investors. The company focuses on developing and commercializing oral immunotherapeutic products for treating gut-mediated diseases. Immuron's Travelan® is already generating revenue and is commercially available in multiple countries with varying indications. This investor engagement aims to provide insights into the company's strategies and performance.
Read more →IMRNIMMURON CEO STEVEN LYDEAMORE TO HOST INVESTOR WEBINAR Echibit 99.1 Immuron CEO, Steven Lydeamore to host an investor webinar Melbourne, Australia
Immuron Limited, headquartered in Australia, is set to host a live investor webinar led by CEO Steven Lydeamore. This event aims to provide insights into the company's developments, including their product Travelan, which targets travelers' diarrhea. Travelan is acknowledged as a legitimate treatment option in several regions, including Australia, Canada, and the U.S., offering a proactive solution for gut health disorders.
Read more →IMRNImmuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
Immuron Limited has responded to a clinical hold issued by the FDA regarding its oral therapeutic for Campylobacter and ETEC. The company collaborated with the Naval Medical Research Center and Johns Hopkins University to address the FDA's safety concerns highlighted during a previous review. A response letter containing additional data has been submitted, and the FDA is expected to provide feedback within 30 days. This proactive step may facilitate the continuation of the clinical trials.
Read more →IMRNUS Department of Defense Uniformed Services University Clinical Evaluation of Travelan Achieves 150 Recruitment Milestone Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study 157 participant
Immuron Limited has announced a significant milestone in the clinical evaluation of Travelan, with 157 participants successfully recruited for the study by the US Department of Defense Uniformed Services University. The trial is designed to evaluate the efficacy of Travelan and another probiotic product in preventing traveler's diarrhea, which remains a critical health issue for military personnel and travelers alike. Despite challenges posed by the COVID-19 pandemic, the study is progressing towards its goal of enrollment completion in approximately 18 months.
Read more →IMRNImmuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
Immuron Limited has announced the granting of a European patent for its drug composition aimed at treating and preventing Clostridioides difficile associated disease. This patent, part of a wider portfolio that includes approvals in Australia, New Zealand, and the United States, underscores the company's commitment to addressing CDI, which has been on the rise globally. The drug, IMM-529, is designed to neutralize toxin B and prevent severe damage to the gut without harming the microbiome. The patent publication will occur on January 25, 2023.
Read more →IMRNImmuron Receives FDA Approval for Travelan IND Application
Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application IND to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by ETEC is now active Plans in place to initiate a Human cli
Read more →IMRNImmuron Submits IND Application To FDA for Travelan
Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the USA Clinical Trial to examine a dosing regimen for Travelan more suited for use by the US milita
Read more →IMRNConstitution of Immuron Limited ACN 063 114 045 Amended at a Meeting of Shareholders held on Monday 21 st November 2022 Table of Contents 1. Definitions and interpretation 1 1.1 Definitions 1 1.2 Interpretation 3 1.3 Rep
at a Meeting of Shareholders held on Monday 21st November 2022 1. Definitions and interpretation 1 1.1 Definitions 1 1.2 Interpretation 3 1.3 Replaceable rules 3 1.4 Compliance with the Act 3 1.5 Transitional 4 1.6 Listing Rules and ASX Settlement Operating Rules only apply if C
Read more →IMRNAGM PRESENTATION 21 NOVEMBER, 2022 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC 1 Certain statements made in this presentation are forward - looking statements and are based on Immuron's current expectations, estimates a
AGM PRESENTATION 21 NOVEMBER, 2022 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC 1 Certain statements made in this presentation are forward - looking statements and are based on Immuron's current expectations, estimates and projections . Words such as "anticipates," "expects," "i
Read more →IMRNImmuron completes strategic investment in leading gut health biotech Ateria Health
Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October 2022): Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateri
Read more →IMRNLevel 3, 62 Lygon Street, Carlton South, Victoria AUSTRALIA 3053 www.immuron.com ABN: 80 063 114 045 Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735 Immuron CEO, Steven Lydeamore to present at AusBioInvest Melb
Level 3, 62 Lygon Street, Carlton South, Victoria AUSTRALIA 3053 www.immuron.com ABN: 80 063 114 045 Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735 Immuron CEO, Steven Lydeamore to present at AusBioInvest Melbourne, Australia, October 27 , 2022 : Immuron Limited (ASX :
Read more →IMRNImmuron CEO, Steven Lydeamore to present at AusBioInvest
MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated
Read more →IMRNIMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2022 ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Date and Time of Meeting: 21 November 2022 at 4.00pm Place of Meeting: Level 2, 62 Lygon
(ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2022 ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Date and Time of Meeting: 21 November 2022 at 4.00pm Level 2, 62 Lygon Street, Carlton, Victoria, This Meeting will be held in person at the above venue and will not be held
Read more →IMRNImmuron strategic investment in leading gut health biotech Ateria Health
Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £1.47m, expiring on 31 July 2023 Ateria Heal
Read more →IMRNImmuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
Clinical Trial Master Service Agreement with US-based Pharmaron Executed Investigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a Controlled Human Infection Model (CHIM) clinical trial in 60 healthy v
Read more →IMRNImmuron Limited Appendix 4E 30 June 2022 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2022 Name of entity: Immuron Limited ABN: 80 063 114 045 Year ended: 30 June 2022 Previous period: 30 June
Name of entity: Immuron Limited ABN: 80 063 114 045 Year ended: 30 June 2022 Previous period: 30 June 2021 Results for announcement to the market $ Revenue from ordinary activities Up 424.9 % to 765,193 Loss from ordinary activities after tax attributable to
Read more →IMRNImmuron CEO, Steven Lydeamore, to host an investor webinar
MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invites investors to join a li
Read more →IMRNImmuron Update on IMM-124E SARS-CoV-2 Research Melbourne, Australia
Immuron Update on IMM-124E SARS-CoV-2 Research Melbourne, Australia, August 19, 2022: Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated disease
Read more →IMRNImmuron Update on IMM-124E SARS-CoV-2 Research
MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has de
Read more →IMRNImmuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic
MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced t
Read more →IMRNImmuron North American Travelan Sales up 494% and Global sales up 431%
North American FY22 Travelan® sales increased by +494% to $0.6M Global sales increased by 431% to $0.9M Australian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and gl
Read more →IMRNImmuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to an
Read more →IMRNImmuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic
US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA) Two human phase II clinical trials to be conducted. One trial will focus on the ability of the hyperimmune product to prevent infectious diarrhea caused by ETEC and sc
Read more →IMRNUS Department of Defense Uniformed Services University Clinical Evaluation of Travelan UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services Univ
Department of Defense Uniformed Services University Clinical Evaluation of Travelan Melbourne, Australia, May 09, 2022: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products f
Read more →IMRNImmuron appoints Mr. Steven Lydeamore as Chief Executive Officer
MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to ann
Read more →IMRNASX Announcement 5 May 2022 Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing ora
Immuron appoints Mr. Steven Lydeamore as Chief Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce
Read more →IMRNImmuron Travelan Global sales up 216%
North American Travelan® sales up by 185% YoY in Q3 FY22 Global sales up 216% YoY in Q3 FY22. YTD March 31, FY22 worldwide Travelan® sales reached AU $392K, increasing 340% YoY. MELBOURNE, Australia, April 27, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), a
Read more →IMRNImmuron North American Travelan sales up 185% Global sales up 216% Key Highlights: North American Travelan sales up by 185% YoY in Q3 FY22 Global sales up 216% YoY in Q3 FY22. YTD March 31, FY22 worldwide Travelan sales
North American Travelan sales up 185% Global sales up 216% Melbourne, Australia, April 27, 2022: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated
Read more →IMRNImmuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’ Travelan Investigational New Drug (IND) application advances Clinical trial Synopsis complete and plans in place to conduct a controll
Read more →IMRNASX Announcement Wed 16 March 2022 Appointment of Paul Brennan as Non-Executive Director Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral im
of Paul Brennan as Non-Executive Director Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the
Read more →IMRNImmuron Limited Appendix 4D Half-year 31 December 2021 Name of entity: Immuron Limited ABN: Half-year ended: Previous period: 80 063 114 045 31 December 2021 31 December 2020 Results for announcement to the market $ Reve
Immuron Limited Appendix 4D Half-year 31 December 2021 Name of entity: Immuron Limited ABN: Half-year ended: Previous period: 80 063 114 045 31 December 2021 31 December 2020 for announcement to the market $ Revenue from ordinary activities Up 1,037.2% to 230,964 Ne
Read more →IMRNImmuron Receives AUD $306,154 R&D Tax Concession Refund
MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to an
Read more →IMRNImmuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to an
Read more →IMRNImmuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for Travelan U.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to support the Travelan clinical development effort Total Award AU $6.2 (USD $4.45) million to exami
Read more →IMRNImmuron Awarded $6.2 Million to Clinically Evaluate a Military Strength Dosing Regimen for Travelan Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for Travelan U.S N
Awarded $6.2 Million to Clinically Evaluate a Military Strength Dosing Regimen for Travelan Australia, January 12, 2022: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the p
Read more →IMRNIMMURON LIMITED (ASX: IMC) Wednesday, 15 th December 2021: Results of Annual General Meeting Immuron Limited (ASX: IMC; NASDAQ: IMRN) wishes to advise that all resolutions were carried by a poll at the Annual General Mee
Wednesday, 15th December 2021: Results of Annual General Meeting (ASX: IMC; NASDAQ: IMRN) wishes to advise that all resolutions were carried by a poll at the Annual General Meeting held earlier today. In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporation
Read more →IMRNIMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2021 ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Date of Meeting: Wednesday, 15 December 2021 Time of Meeting: 4.30PM (Melbourne time) Du
code: IMC, NASDAQ code: IMRN) OF 2021 ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM to the ongoing COVID-19 pandemic, the meeting will be held virtually. Details on how to participate virtually' are provided in the Virtual Meeting Online Guide attached as Annexure A to thi
Read more →IMRNUS DoD Uniformed Services University Travelers' Diarrhea Clinical Update Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the effi
DoD Uniformed Services University Travelers' Diarrhea Clinical Update Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan and two other non- antibiotic OTC products in Traveler
Read more →IMRNUS DoD Naval Medical Research Center Clinical Update Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed. IND submission to the U.
DoD Naval Medical Research Center Clinical Update Australia, November 10, 2021: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pa
Read more →IMRNIMM124E - Demonstrates Antiviral T-Cell Immunity Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration
IMM124E - Demonstrates Antiviral T-Cell Melbourne, Australia, October 08, 2021: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut p
Read more →IMRNImmuron L imited ABN 80 063 114 045 Annual report - 30 June 2021 Corporate directory 1 Chairman's letter 4 Review of operations and activities 7 Directors' report 12 Directors and company secretary 12 Principal activitie
report - 30 June 2021 Corporate directory 1 Chairman's letter 4 Review of operations and activities 7 Directors' report 12 Directors and company secretary 12 Principal activities 12 Dividends - Immuron Limited 12 Review of operations 12 Significant changes in the state of affair
Read more →IMRNDirector resignation Melbourne, Australia
Australia, September 24, 2021: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of Mr Pet
Read more →IMRNImmuron Director resignation
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received t
Read more →IMRNImmuron planned Acquisition of R&D Vaccine Company
MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today would like
Read more →IMRNImmuron Limited Appendix 4E 30 June 2021 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2021 Name of entity: Immuron Limited ABN: Year ended: Previous period: 80 063 114 045 30 June 2021 30 June
Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2021 Name of entity: Immuron Limited ABN: Year ended: Previous period: 80 063 114 045 30 June 2021 30 June 2020 Results for announcement to the market $ Revenue from ordinary activities Do
Read more →IMRNJuly 2021 Market Update Immuron Limited ( Immuron ) refers to its market update of 8 June 2021 advising the market that it had lodged a submission with the ASX regarding a proposed major transaction. ASX confirmed to Imm
Immuron Limited (Immuron) refers to its market update of 8 June 2021 advising the market that it had lodged a submission with the ASX regarding a proposed major transaction. ASX confirmed to Immuron on 11 June 2021 that if it proceeds with the proposed transaction, that ASX wi
Read more →IMRNJune 2021 Market Update Further to recent ASX Announcement requesting a Trading Halt and subsequent Suspension of Trading as well as questions from shareholders. The company is limited in the detail that can be released
Further to recent ASX Announcement requesting a Trading Halt and subsequent Suspension of Trading as well as questions from shareholders. The company is limited in the detail that can be released at this time while the ASX consider a submission it has requested from the Compan
Read more →IMRNIMM124E - May offer a New modality for Inhibition of SARS-CoV-2 Key Points Monash University Research Update on SARS-CoV-2 program Biomedicine Discovery Institute initiates program to isolate and identify the inhibitory
IMM124E - May offer a New modality for Inhibition of SARS-CoV-2 Melbourne, Australia, May 13, 2021: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention a
Read more →IMRNImmuron Limited Appendix 4D Half-year 31 December 2020 Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2020 Previous period: 31 December 2019 Results for announcement to the market $ Reve
Half-year 31 December 2020 Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2020 Previous period: 31 December 2019 Results for announcement to the market $ Revenue from ordinary activities Down (98.7)% to 20,309 Net loss af
Read more →IMRNImmuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to annou
Read more →IMRNImmuron SARS-CoV-2 Research Agreement with Monash University
Immuron’s Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies. A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-
Read more →IMRNAppendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen
of Director's Interest Notice of Director's Interest Notice or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Name of Entity: Immuron Limited (ASX: IMC) ABN: 80 063 11
Read more →IMRNImmuron Receives AUD $358,280 R&D Tax Concession Refund
MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under
Read more →IMRNNotice Under Section 708A (5) of the Corporations Act (ASX Code: IMC) This notice is given under paragraph (5)(e) of section 708A of the Corporations Act. Type Shares Class Ordinary ASX code IMC Date of Issue 13 November
Under Section 708A (5) of the Corporations Act notice is given under paragraph (5)(e) of section 708A of the Corporations Act. Type Shares Class Ordinary ASX code IMC Date of Issue 13 November 2020 Number Issued 2,737,500 Issue price per security: A$0.08 per share Limited give
Read more →IMRNProposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday
Announcement Summary Date of this announcement Friday November 13, 2020 The Proposed issue is: placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number
Read more →IMRNUS DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine Key Points NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETEC Immuron executes a Rese
DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine Australia, November 09, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the preven
Read more →IMRNFORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES - OCTOBER, 2020 JERRY KANELLOS, Ph.D. CEO NASDAQ: IMRN ASX: IMC 1 DEVE L OPMENT PIPELINE 2 TRAVELAN COMMERCIAL PROFILE: A UD
FORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES - OCTOBER, 2020 JERRY KANELLOS, Ph.D. CEO NASDAQ: IMRN ASX: IMC 1 DEVE L OPMENT PIPELINE 2 TRAVELAN COMMERCIAL PROFILE: A UD $ - 3 $500,000 $1,000,000 $1,500,000 $2,000,000 $2,500,000
Read more →IMRNImmuron Travelers’ Diarrhea Market Update
Immuron’s IMM-124E IND Program recommences Uniformed Services University to recommence planned Travelers’ Diarrhea clinical study COVID-19 - Consultancy Agreement with Infectious Disease Epidemiologist at Wayne State University MELBOURNE, Australia, Oct. 12, 2020 (GLOBE NEWSWI
Read more →IMRNImmuron Travelers' Diarrhea Market Update Key Points Immuron's IMM-124E IND Program recommences Uniformed Services University to recommence planned Travelers' Diarrhea clinical study COVID-19 - Consultancy Agreement with
Travelers' Diarrhea Market Update Australia, October 12, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today i
Read more →IMRNTime of AGM Clarification Melbourne, Australia
of AGM Clarification Australia, September 30, 2020: Immuron Limited (ASX: IMC; NASDQ: IMRN), would like to clarify the time that the Company's Annual General Meeting (AGM) will be held as disclosed on the Notice of 2020 AGM previously released. Date of Meeting: Thursday, 29 th
Read more →IMRNImmuron Limited ABN 80 063 114 045 Annual report - 30 June 2020 Corporate directory 1 Chairman's letter 3 Review of operations and activities 6 Directors' report 10 Directors and company secretary 11 Principal activities
Annual report - 30 June 2020 Corporate directory 1 Chairman's letter 3 Review of operations and activities 6 Directors' report 10 Directors and company secretary 11 Principal activities 11 Dividends - Immuron Limited 11 Review of operations 11 Significant changes in the state of
Read more →IMRNImmuron Limited Appendix 4E 30 June 2020 Immuron Limited Appendix 4E Year ended 30 June 2020 Name of entity: Immuron Limited ABN: 80 063 114 045 Year ended: 30 June 2020 Previous period: 30 June 2019 Results for announce
Year ended 30 June 2020 Name of entity: Immuron Limited ABN: 80 063 114 045 Year ended: 30 June 2020 Previous period: 30 June 2019 Results for announcement to the market $ Revenue from ordinary activities Up 5.5 % to 2,518,566 Loss from ordinary activities aft
Read more →IMRNThis appendix is not available as an online form Please fill in and submit as a PDF announcement +Rule 2.7 Appendix 2A Application for quotation of +securities Information or documents not available now must be given to
This appendix is not available as an online form Please fill in and submit as a PDF announcement +Rule 2.7 Application for quotation of +securities Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX bec
Read more →IMRNImmuron Limited Announces Closing of $20.0 Million Registered Direct Offering
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens,
Read more →IMRNImmuron Announces US $20.0 Million Registered Direct Offering Melbourne, Australia
Announces US $20.0 Million Registered Direct Offering Australia, July 22, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated p
Read more →IMRNImmuron Announces $20.0 Million Registered Direct Offering
MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced
Read more →IMRNImmuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points
Immuron’s IMM-124E used to manufacture Travelan® and Protectyn® demonstrates antiviral activity against the COVID-19 virus in laboratory studies Immuron’s technology platform offers a potential new oral therapeutic approach to target SARS-CoV-2 in the GI Tract MELBOURNE, Austra
Read more →IMRNUS DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting
DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic Australia, July 20, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoth
Read more →IMRNImmuron Limited Appendix 4D Half-year 31 December 2019 Name of entity: Immuron Limited ABN: Half-year ended: Previous period: 80 063 114 045 31 December 2019 31 December 2018 Results for announcement to the market $ Reve
Name of entity: Immuron Limited ABN: Half-year ended: Previous period: 80 063 114 045 31 December 2019 31 December 2018 for announcement to the market $ Revenue from ordinary activities Up 59.1% to 1,556,623 Net loss after tax (from ordinary activities) for the peri
Read more →IMRNImmuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc. Immuron executes a Research Agreement with CSIRO to develop a new oral therapeutic targeting Campylobacter and ETEC for clinical evaluation Vaccination program i
Read more →IMRNImmuron and CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense Key Points Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Militar
and CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense Australia, June 19, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for
Read more →IMRNUS DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral th
US DoD Naval Medical Research Center Requests Meeting FDA for Guidance on two Phase 2 trials to Prevent Acute Melbourne, Australia, June 9, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral im
Read more →IMRNImmuron Board Relinquish Cash Payment of Fees
MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced that the cash p
Read more →IMRNImmuron Board Relinquish Cash Payment of Fees Melbourne, Australia
Board Relinquish Cash Payment of Fees Australia, April 27, 2020: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced that t
Read more →IMRNImmuron North American Travelan Sales Up 95%, Global Sales Up 60%
North American sales up by 95% YoY in Q3 FY20 Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20. YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57% YoY. In Australia, Q3 FY20 gross sales grew by 35% YoY to $475K. In the USA, Q3 FY20 gross
Read more →IMRNImmuron Global Sales Up 60% Key Highlights: Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20. YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57% YoY. In Australia, Q3 FY20 gross sal
Australia, April 20, 2020: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the sales results of its commercially availa
Read more →IMRNResignation of CEO & Director and cost cutting amidst COVID-19 Wednesday 25 March 2020 (Melbourne) The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact o
CEO & Director and cost cutting amidst COVID-19 Wednesday 25 March 2020 (Melbourne) The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 The World is in the midst of an unprecedented health crisis
Read more →IMRNImmuron Provides Update on First Half of FY20 Results
Strong continued growth of Travelan® sales reported in all markets Global sales reached USD $1.1 million (AUD $1.68 million) for first half FY 2020 up 55% from first half FY 2019 North American Travelan® sales up by 98% YoY in the first half of FY20 IMM-124E/Travelan® US regis
Read more →IMRNImmuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak
Wuhan coronavirus outbreak expanding to global health emergency Outbreak while viral in nature highlights the role of global travel leading to respiratory and gastrointestinal infections Increased global travel over the past decade to sites endemic for gastrointestinal infectio
Read more →IMRNMelbourne, Australia, January 28, 2020:
North American Travelan in the first half of FY20 Melbourne, Australia, January 28, 2020: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated disea
Read more →IMRNGary S.
Gary S. Jacob to Present at Biotech Showcase Conference on January 13, 2020 Melbourne, Australia, January 8, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for
Read more →IMRNImmuron CEO Dr. Gary S. Jacob to Present at Biotech Showcase Conference on January 13, 2020
MELBOURNE, Australia, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that CE
Read more →IMRNImmuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea
Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD) Phase 3 clinical trial of IMM-124E to prevent TD planned for 2020 Previous clinical trial data on IMM-124E from earlier studies provides support for d
Read more →IMRNImmuron Plans Phase 3 trial for IMM-124E
Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers' Diarrhea Melbourne, Australia, November 21, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for th
Read more →IMRNFORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES - NOVEMBER 2019 NASDAQ: IMRN ASX: IMC GARY S.
1 1 FORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES - NOVEMBER 2019 NASDAQ: IMRN ASX: IMC GARY S. JACOB, Ph.D. CEO 2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron's current
Read more →IMRNImmuron Receives AUD $0.53M R&D Tax Concession Refund
MELBOURNE, Australia, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to an
Read more →IMRNReceives AUD $0.53M R&D Tax Concession Refund
Receives AUD $0.53M R&D Tax Concession Refund Australia, November 4, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathog
Read more →IMRNMelbourne, Australia, October 29, 2019:
XBRL data with the SEC Melbourne, Australia, October 29, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN) ("Immuron" or the "Company"), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of g
Read more →IMRNImmuron Announces Resignation of Board Member
Immuron Announces Resignation of Board Member Melbourne, Australia, October 17, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut med
Read more →IMRNNorth American Q1 Sales Up 111% YoY
North American Q1 Sales Up 111% YoY Melbourne, Australia, October 14, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut-mediated path
Read more →IMRNImmuron North American Q1 Sales Up 111% YoY
First Quarter of FY2020 (Q1) North American sales grew by 111% YoY to $269K AUD Q1 US Travelan® sales increased by +81% YoY to $232K AUD Global Immuron sales continued an upward trend in Q1 with a +54% YoY sales increase, reaching $741K AUD In Australia, Q1 Travelan® sales inc
Read more →IMRNNotice of 2019 Annual General Meeting and
Notice of 2019 Annual General Meeting and Explanatory Memorandum Date of Meeting: Wednesday, 6 November 2019 Time of Meeting: 3:30pm (Melbourne, Victoria, Australia time) Registration from: 3:15pm (Melbourne, Victoria, Australia time) Place of Meeting: Level 2, 62 Lygon Str
Read more →IMRNNew U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter Key Highlights: AU $5.5 (USD $3.7) million funding approved by the U.S. Depart
U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter AU $5.5 (USD $3.7) million funding approved by the U.S. Department of Defense to develop and clinically evaluate a new oral therapeutic tar
Read more →IMRNReports Immuron's Travelan demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating
Reports Immuron's Travelan demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of traveler's diarrhea Melbourne, Australia, September 4, 2019: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceut
Read more →IMRNNo dividends have been paid or declared by the
Name of entity: Immuron Limited ABN: 80 063 114 045 Year ended: 30 June 2019 Previous period: 30 June 2018 Results for announcement to the market $ Revenue from ordinary activities Up 29.5% to 2,387,426 Loss from ordinary activities after tax attributable to members Up 53.
Read more →IMRNCorporate Governance Council Principles and Recommendations
Rules 4.7.3 and 4.10.31 Corporate Governance Council Principles and Recommendations Name of entity Immuron Limited ABN/ARBN Financial year ended 80 063 114 045 30 June 2019 Our corporate governance statement2 for the above period above can be found at:3 these pages of ou
Read more →IMRNImmuron to Commence Non-Deal Investor Roadshow
MELBOURNE, Australia, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today is pleased to rel
Read more →IMRNFORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES - AUGUST 2019 NASDAQ: IMRN ASX: IMC GARY S. JACOB, Ph.D. CEO 2 2 Certain statements made in this presentation are forward - l
1 1 FORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES - AUGUST 2019 NASDAQ: IMRN ASX: IMC GARY S. JACOB, Ph.D. CEO 2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron's current ex
Read more →IMRNImmuron Reports Results in Severe
Immuron Reports Results in Severe Hepatitis Clinical Trial Melbourne, Australia, August 08, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut media
Read more →IMRNImmuron Reports Results in Severe Alcoholic Hepatitis Clinical Trial
MELBOURNE, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the topline resu
Read more →IMRNImmuron completes capital raising of USD $1.35M Melbourne, Australia
completes capital raising of USD $1.35M Australia, July 22, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to advise
Read more →IMRNAnnounces Proposed Public Offering of ADSs
Announces Proposed Public Offering of ADSs Melbourne, Australia, July 17, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseas
Read more →IMRNImmuron Prices Underwritten Public Offering of ADSs
MELBOURNE, Australia, July 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced the pri
Read more →IMRNImmuron to Host Investor Webinar on July 18 to Provide Update on Recent Developments
MELBOURNE, Australia, July 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced today that it will participate in an investor webinar and Q&A session on Thursday, July 18, 2019, at 10:30 a.m. EST (US time), host
Read more →IMRNImmuron North American revenue surges by 52% in FY19
Immuron FY19 revenue surged by 52% in North America, reaching $1.16M. In the USA, FY19 Travelan® sales exceeded the $1M AUD milestone for the first time and grew by +32% to $1.02M AUD. In May 2019, USA Travelan® sales achieved a record-breaking $182K AUD. The first Canadian sa
Read more →IMRNImmuron Announces Proposed Public Offering of ADSs
MELBOURNE, Australia, July 16, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that it
Read more →IMRNImmuron Directors Increase Shareholdings in the Company
MELBOURNE, Australia, June 25, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company wishes to advise that two of its Directors, Mr Peter Anastasiou and Mr Daniel Pollock have recently acquired on-market 1,000,000 (25,000 ADS e
Read more →IMRNof Director's Interest Notice
of Director's Interest Notice of Director's Interest Notice or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. 30/9/2001. Amended 01/01/11 Name of Entity: Immuron Limi
Read more →IMRNImmuron to Commence US Non-Deal Institutional Investor Roadshow
MELBOURNE, Australia, June 19, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of many gut mediated pathogens, today is ple
Read more →IMRNFORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES - JUNE 2019 NASDAQ: IMRN ASX: IMC GARY S.
1 1 FORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES - JUNE 2019 NASDAQ: IMRN ASX: IMC GARY S. JACOB, Ph.D. CEO 2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron's current expe
Read more →IMRNDepartment of Defense Reports Final Results from Travelan Shigellosis Challenge Study
Department of Defense Reports Final Results from Travelan Shigellosis Challenge Study Australia, June 12, 2019: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention
Read more →IMRNImmuron Announces the Closing of Public Offering of ADSs
MELBOURNE, Australia, May 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced the clos
Read more →IMRNImmuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on
CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019 Australia, April 29, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immuno-therapeutics for the treatment of gut
Read more →IMRNImmuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019
MELBOURNE, Australia, April 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immuno-therapeutics for the treatment of gut mediated diseases, today announced that CEO Dr. G
Read more →IMRNImmuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
MELBOURNE, Australia, April 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced the ap
Read more →IMRNAppendix 3X Initial Director's Interest Notice Rule 3.19A.1 Appendix 3X Initial Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents g
Director's Interest Notice Initial Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Name of entity Immuron Limited ABN 80 063
Read more →IMRNFORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES - APRIL 2019 NASDAQ: IMRN ASX: IMC
1 1 FORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES - APRIL 2019 NASDAQ: IMRN ASX: IMC 2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron's current expectations, estimates and
Read more →IMRNImmuron sales surge by 66% in the Third Quarter of FY19
Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019. In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY. In the US Q3 sales of Travelan® were similarly strong, growing 60% YoY. During Q3 FY19, Immuron received t
Read more →IMRNImmuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea
Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ Diarrhea Company anticipates significant inflection in sales with successful FDA registration of IMM-124E Company to pursue rapid path for clinical development of IMM-124E Travelan® safely and effectively
Read more →IMRNImmuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile
C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues patent covering Immuron’s drug composition for treatment of C. difficile Aust
Read more →IMRNImmuron Limited ABN 80 063 114 045 Interim financial report for the half-year 31 December 2018 Immuron Limited ABN 80 063 114 045 Interim financial report - 31 December 2018 Contents Page Corporate directory 1 Financial
Interim financial report for the half-year 31 Limited ABN 80 063 114 045 Interim financial report - 31 December 2018 Contents Page Corporate directory 1 Financial statements 3 Notes to the condensed consolidated financial statements 7 This interim financial report does not
Read more →IMRNImmuron sales surge by 66% in the Third Quarter of FY19 Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending
Immuron sales surge by 66% in the Third Melbourne, Australia, April 15, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today a
Read more →IMRNImmuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile Company Provides Update on Status of IMM-529 Clinical Trial and New Strategic Focus Key Points C. difficile remains a major medical problem,
Receives U.S. Patent on Drug Composition to Treat Clostridium difficile Provides Update on Status of IMM-529 Clinical Trial and New Strategic Focus Australia, March 19, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing
Read more →IMRNImmuron Limited Appendix 4D Half-year 31 December 2018 Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2018 Previous period: 31 December 2017 Results for announcement to the market $ Reve
Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2018 Previous period: 31 December 2017 for announcement to the market $ Revenue for ordinary activities Up 6.4 % to 978,233 Net loss after tax (from ordinary activities) for
Read more →IMRNTravelan FY19 1st Half Update and Geographic Expansion into North America Key Highlights: Immuron achieved 7% YoY growth in worldwide sales for the first half of FY19. In the US, Travelan exhibited double-digit growth fo
FY19 1st Half Update and Geographic Expansion into North America Australia, January 29, 2019: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated di
Read more →IMRNImmuron Receives $1.19M R&D Tax Concession Refund
MELBOURNE, Australia, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund o
Read more →IMRNImmuron Receives $1.19M R&D Tax Concession Refund January 3 rd , 2019, Melbourne, Australia Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the "Company") is pleased to announce that under the Australian Government's Research a
Receives $1.19M R&D Tax Concession Refund 3rd, 2019, Melbourne, Australia Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the "Company") is pleased to announce that under the Australian Government's Research and Development Income Tax Concession incentive program, the Company has rec
Read more →IMRNRule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New Issue Announcement, Application for Quotation of Additional Securities and Agreement Information or documents not available now must be given to ASX as soon as available.
2.7, 3.10.3, 3.10.4, 3.10.5 for Quotation of Additional or documents not available now must be given to ASX as soon as available. and documents given to ASX become ASX's property and may be made public. 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/0
Read more →IMRNImmuron Appoints Gary S. Jacob, Ph.D., Experienced US Based Biotechnology Executive, as CEO
MELBOURNE, Australia, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Immuron Limited, (IMC or the Company), (ASX: IMC; NASDAQ: IMRN), is pleased to announce the appointment of Gary S. Jacob as Chief Executive Officer. Dr Jacob is the former Chairman, President and Chief Executive Officer of S
Read more →IMRNIMMURON LIMITED (ASX: IMC) Monday, 19 th November 2018: Results of Annual General Meeting The Company wishes to advise that all resolutions were carried on a show of hands. In accordance with Listing Rule 3.13.2 and Sect
Monday, 19th November 2018: Results of Annual General Meeting The Company wishes to advise that all resolutions were carried on a show of hands. In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in
Read more →IMRNNASH clinical trial presentation and continued revenue growth Key Highlights: Professor Arun Sanyal to present IMM-124E NASH clinical trial results at the Liver Meeting in San Francisco Travelan on display at HealthEd Au
NASH clinical trial presentation and continued revenue growth Australia, November 9, 2018: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many g
Read more →IMRNImmuron lodges 20-F - USA Annual Report Melbourne, Australia
20-F - USA Annual Report Australia, November 1, 2018: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical company wishes to advise that it has today filed its Annual Report on Form 20-F containing audited consolidated financial statements for t
Read more →IMRNTranscript of
Transcript of October 17, 2018 Interview of Jerry Kanellos, CEO of Immuron Limited, on the RedChip Money Report [Dave] Now you're developing immunotherapies for gut-related gut-mediated diseases. Tell us about your platform and where you're at? [Jerry] Yeah, sure Dave. Immuro
Read more →IMRNImmuron Limited 's CEO Interviewed in US on the RedChip Money Report Melbourne, Australia
Limited's CEO Interviewed in US on the RedChip Money Report Melbourne, Australia, October 16, 2018: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antib
Read more →IMRNIMMURON LIMITED ABN: 80 063 114 045 Notice of Annual General Meeting and Explanatory Memorandum Date of Meeting: 19 November 2018 Time of Meeting: 3:30pm AEDT Registration from 3:15pm AEDT Place of Meeting: Level 2, 62 L
of Annual General Meeting and Explanatory Memorandum Date of Meeting: 19 November 2018 Time of Meeting: 3:30pm AEDT Registration from 3:15pm AEDT Place of Meeting: Level 2, 62 Lygon Street, Carlton, Victoria, Australia 3053 is an important document. It should be read in i
Read more →IMRNImmuron Limited ABN 80 063 114 045 Annual report for the year ended 30 June 2018 Immuron Limited ABN 80 063 114 045 Annual Report- 30 June 2018 Contents Page Corporate directory 1 Intellectual property report 6 Directors
the year ended 30 June 2018 Limited ABN 80 063 114 045 Report- 30 June 2018 Page Corporate directory 1 Intellectual property report 6 Directors' report 7 Auditor's independence declaration 28 Financial statements Consolidated statement of profit or loss and other compr
Read more →IMRNUS Department of Defense Reports Travelan Protects Against Shigella in Primates Key Highlights: Travelan pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completed Travelan prevented cl
Department of Defense Reports Travelan Protects Against Shigella in Primates Australia, September 05, 2018: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prev
Read more →IMRNImmuron Limited Appendix 4E 30 June 2018 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2018 Name of entity: Immuron Limited ABN or equivalent company reference: 80 063 114 045 Current financial
Year ended 30 June 2018 Name of entity: Immuron Limited ABN or equivalent company reference: 80 063 114 045 Current financial period: 30 June 2018 Corresponding financial period: 30 June 2017 Results for announcement to the market $ Revenue for ordinary activities
Read more →IMRNImmuron Reports Record Revenue Exceeding AU$2 million for the FY18 year
Global Immuron Ltd sales revenue reached an AU$2million milestone continuing its upward trend and enjoying a 29% sales increase compared to FY17. US Travelan® sales continue to exceed expectations growing to AU$765k which represents a 114% increase over FY17. In Australia Trave
Read more →IMRNImmuron Announces it has Received a European Patent Grant for NASH treatment
MELBOURNE, Australia, July 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediat
Read more →IMRNUS Department of Defense Research Collaboration Moves Forward Key Highlights: Three US Defense Health funded research projects on Travelan successfully completed Studies commissioned by the US Department of Defense to ev
Department of Defense Research Collaboration Moves Forward Australia, July 16, 2018: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut media
Read more →IMRNImmuron Announces it has Received a European Patent Grant for NASH treatment Melbourne, Australia
Immuron Announces it has Received a European Patent Grant for NASH treatment Australia, July 11, 2018: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally delivered targeted polyclonal
Read more →IMRNCOMPANY ANNOUNCEMENT Resignation of Joint Company Secretary Melbourne, Australia, 29 June 2018: Australian biopharmaceutical company Immuron Limited (ASX: IMC) (NASDAQ: IMRN) (the "Company"), wishes to advise that Mr. Pe
of Joint Company Secretary Australia, 29 June 2018: Australian biopharmaceutical company Immuron Limited (ASX: IMC) (NASDAQ: IMRN) (the "Company"), wishes to advise that Mr. Peter Vaughan has accepted a new executive appointment and as a result he has stepped down as Joint Com
Read more →IMRNImmuron Announces Board Appointment Melbourne, Australia, 26 June 2018: Australian biopharmaceutical company Immuron Limited (ASX: IMC), is pleased to announce the appointment of New York based Mr. Richard Jay Berman to
Announces Board Appointment Australia, 26 June 2018: Australian biopharmaceutical company Immuron Limited (ASX: IMC), is pleased to announce the appointment of New York based Mr. Richard Jay Berman to serve as a Director of the Company effective from 1 July Berman's business c
Read more →IMRNImmuron Announces Board Appointment
MELBOURNE, Australia, June 25, 2018 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company Immuron Limited (ASX:IMC), is pleased to announce the appointment of New York based Mr. Richard Jay Berman to serve as a Director of the Company effective from 1 July 2018. Richard Berma
Read more →IMRNImmuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
MELBOURNE, Australia, May 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated
Read more →IMRNImmuron's Travelan ® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets Key Highlights: • US Travelan ® sales continue an upward trend with a 95% increase in the Third Quart
Travelan Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets Australia, April 23, 2018: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted poly
Read more →IMRNImmuron’s Travelan Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets
US Travelan® sales continue an upward trend with a 95% increase in the Third Quarter of 2018 compared to the same period last year. YTD US sales (End March 2018) climbed to $AUD501K, representing a strong 178% increase on the same period last year. Travelan® YTD sales in Austral
Read more →IMRNImmuron CEO to Present at RedChip Global Online Growth Conference
MELBOURNE, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), Australian microbiome biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated a
Read more →IMRNPage 1 of 3 15 July 2001 Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Immuron Limited ACN/ARSN 063 114 045 1. Details of substantial holder (1) Na
604 Page 1 of 3 15 July 2001 Corporations Act 2001 Notice of change of interests of substantial To Company Name/Scheme Immuron Limited ACN/ARSN 063 114 045 1. Details of substantial holder (1) Name Peter Anastasiou ACN/ARSN (if applicable) N/A There was a change in the inte
Read more →IMRNImmuron Limited Interim Financial Report - 31 December 2017 Contents Interim Financial Statements Consolidated Statement of Comprehensive Income 1 Consolidated Balance Sheet 2 Consolidated Statement of Changes in Equity
Financial Report - 31 December 2017 Contents Interim Financial Statements Consolidated Statement of Comprehensive Income 1 Consolidated Balance Sheet 2 Consolidated Statement of Changes in Equity 3 Consolidated Statement of Cash Flows 4 Notes to the Consolidated Financial Stat
Read more →IMRNImmuron Completes A$5.1M Placement to US Fund Melbourne, Australia
Completes A$5.1M Placement to US Fund Melbourne, Australia, March 16, 2018: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment
Read more →IMRNImmuron Progresses Discussions with Institutional Funds
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediate
Read more →IMRNImmuron Announces A$5.1M Private Placement to U.S. Fund
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediat
Read more →IMRNImmuron Commences US Non-Deal Institutional Investor Roadshow
MELBOURNE, Australia, March 12, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its latest Company Presentation ahead of commencing a comprehensive roadshow to inves
Read more →IMRNMonday 12 th March 2018 Kat Kidson Principal Adviser Listings Compliance (Melbourne) ASX Compliance Pty Ltd Level 4, North Tower Rialto, 525 Collins Street, Melbourne, VIC. 3000 Sent via email: kate.kidson@asx.com.au and
Adviser Listings Compliance (Melbourne) 4, North Tower Rialto, Collins Street, Melbourne, VIC. 3000 via email: kate.kidson@asx.com.au and tradinghaltsmelbourne@asx.com.au. Request for Trading Halt accordance with ASX Listing Rule 17.1, the Directors of Immuron Limited (the C
Read more →IMRNImmuron Limited Issues Correction to Misleading Halt Announcement Headline
MELBOURNE, Australia, March 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to correct a misleading halt announcement released over the wire yesterday. The misleading statement was headed “Immuron Ltd. ADR (IMRN) Halted due to regula
Read more →IMRNImmuron Reports Positive Results in NASH Clinical Trial
First-In Class Anti-LPS Mechanism of Action confirmed for IMM-124E Results demonstrate excellent safety and tolerability Statistically significant reduction in serum endotoxin/ Lipopolysaccharide (LPS) levels compared to placebo Statistically significant reduction in mean seru
Read more →IMRNCorrection to False and Misleading News Release March 7 th , 2018, Melbourne, Australia : Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the "Company") wishes to correct a false and misleading newswire statement released throu
to False and Misleading News Release 7th, 2018, Melbourne, Australia: Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the "Company") wishes to correct a false and misleading newswire statement released through global newswire services today. false and misleading statement was headed
Read more →IMRNImmuron Limited Appendix 4D Half-Year Ended 31 December 2017 Name of Entity: Immuron Limited ABN: 80 063 114 045 Half-Year Ended: 31 December 2017 Previous Period: 31 December 2016 Results for Announcement to the Market
Ended 31 December 2017 Name of Entity: Immuron Limited ABN: 80 063 114 045 Half-Year Ended: 31 December 2017 Previous Period: 31 December 2016 Revenue for ordinary activities Up 30.7% to $919,138 Net profit after tax (from ordinary activities) for the period attributable to mem
Read more →IMRNTravelan Revenue Grows Significantly in US and Australia Key Highlights: Immuron's flag-ship product Travelan reports revenue in excess of AUS$914K for first 6 months of FY2018 Travelan US experienced a 250% increase in
Travelan Revenue Grows Significantly in US and Australia Melbourne, Australia, February 16, 2018: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of
Read more →IMRNImmuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)
First patients enrolled in Immuron’s IMM-529 clinical study at Hadassah Medical Center in Israel Trial will treat 60 confirmed patients over 28 days to evaluate safety and efficacy of IMM-529 for the treatment of CDI CDI is one of the top superbugs challenging the healthcare in
Read more →IMRNUS Defense Reports Broad Travelan Reactivity to 180 Pathogenic Bacteria including Camylobacter and Shigella Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) and was conducted by
Defense Reports Broad Travelan Reactivity to 180 Pathogenic Bacteria including Camylobacter and Shigella Australia, January 30, 2017: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immu
Read more →IMRNImmuron to Receive $2.16M R&D Tax Concession Refund
Melbourne, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company will receive a cash refund o
Read more →IMRNMARCUM LETTEREAD]
Securities and Exchange Commission Washington, DC 20549 We have read the statements made by Immuron Limited in its Form 6-K dated January 18, 2018. We agree with the statements concerning our Firm in such Form 6-K; we are not in a position to agree or disagree with other state
Read more →IMRNCEO to Present on US Investor TV Show and at Biotech Conference January 10 th , 2018, Melbourne, Australia : Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the "Company") is pleased to advise investors that CEO Dr Jerry Kanell
CEO to Present on US Investor TV Show and at Biotech Conference January 10th, 2018, Melbourne, Australia: Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the "Company") is pleased to advise investors that CEO Dr Jerry Kanellos, was interviewed on The RedChip Money Report US televisi
Read more →IMRNImmuron to Present at RedChip’s Global Online Growth Conference
MELBOURNE, Australia, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to advise investors that CEO Dr Jerry Kanellos is scheduled to present at RedChip’s Global Online Growth Conference on Wednesday, December 6th, 2017, at 4:30pm U
Read more →IMRNVan Leeuwenhoeck Institute Updates Immuron Research Coverage 22 November 2017, Melbourne, Australia: Immuron Limited (ASX:IMC) (the "Company") wishes to advise investors that Van Leeuwenhoeck Institute, a prominent Europ
Leeuwenhoeck Institute Updates Immuron Research Coverage 22 November 2017, Melbourne, Australia: Immuron Limited (ASX:IMC) (the "Company") wishes to advise investors that Van Leeuwenhoeck Institute, a prominent European and US-based Life Sciences Research and Analyst firm ("VL
Read more →IMRNImmuron Granted US Patent for NASH Treatment
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated diseases, is today pleased to an
Read more →IMRNImmuron Granted US Patent for NASH Treatment Melbourne, Australia
Granted US Patent for NASH Treatment Australia, November 14, 2017: Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated diseases, is today
Read more →IMRNImmuron Successfully Completes NASH Phase II Clinical Study Milestone
MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated diseases, announced today that i
Read more →IMRNTravelan Experiences Strong Q1 FY2018 Sales Growth Key Highlights: Significant growth of sales for Immuron's over-the-counter supplement Travelan for Q1 2018 compared to Q1 2017 Travelan US experienced a 197% increase in
Experiences Strong Q1 FY2018 Sales Growth Australia, November 8, 2017: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of many gut mediated diseases,
Read more →IMRNImmuron Ltd. Highlights Market Opportunity Following Recent Studies on Antibiotic Correlation to C. Difficile Infections
MELBOURNE, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut-mediated diseases, today highlighted rece
Read more →IMRNImmuron Limited ABN 80 063 114 045 Annual report for the year ended 30 June 2017 Immuron Limited ABN 80 063 114 045 Annual report - 30 June 2017 Contents Page Corporate directory 1 Intellectual property report 7 Director
Limited ABN 80 063 114 045 report - 30 June 2017 Page Corporate directory 1 Intellectual property report 7 Directors' report 9 Financial statements Consolidated statement of profit or loss and other comprehensive income 31 Consolidated statement of financial position 32 Conso
Read more →IMRNImmuron Highlights Recent Milestones in Quest to Effectively Treat Multiple Forms of Fatty Liver Diseases That Impact Millions
Company’s lead drug candidate IMM-124E is well-positioned to pioneer successful treatment for NASH and NAFLD, diseases for which there is no proven effective treatment Company provides overview of existing clinical trials for IMM-124E that upon execution and analysis, will estab
Read more →IMRNPage 1 of 2 15 July 2001 Form 605 Corporations Act 2001 Section 671B Notice of ceasing to be a substantial holder To Company Name/Scheme Immuron Limited ACN/ARSN 063 114 045 1. Details of substantial holder (1) Name Chri
of ceasing to be a substantial holder To Company Name/Scheme Immuron Limited ACN/ARSN 063 114 045 Details of substantial holder (1) Name Chris Retzos ACN/ARSN (if applicable) The holder ceased to be a substantial holder on 9 / June / 2017 The previous notice was given to the
Read more →IMRNAppendix 4E - Preliminary Final Report For the Financial Year Ended 30 June 2017 Current Reporting Period - Year Ended 30 June 2017 Previous Reporting Period - Year Ended 30 June 2016 In compliance with Listing Rule 4.2A
Appendix 4E - Preliminary Final Report For the Financial Year Ended 30 June 2017 Current Reporting Period - Year Previous Reporting Period - Year Ended 30 June 2016 In compliance with Listing Rule 4.2A. 30 June 2017 30 June 2016 Revenues Up 39% to 1,396,197 from 1,001,07
Read more →IMRNImmuron Opens Clinical Site to Evaluate Safety and Efficacy of IMM-529 for Treatment of Clostridium Difficile Infection (CDI) Key Highlights: Immuron's clinical study of IMM-529 initiated at Hadassah Medical Centre First
Immuron Opens Clinical Site to Evaluate of IMM-529 for Treatment of Clostridium Difficile Infection (CDI) Melbourne, Australia, August 28th, 2017: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercial
Read more →IMRNIMMURON LIMITED Securities Trading Policy Adopted by Board Resolution on: Thursday 17 th August 2017 Page 1 of 7 1 Purpose This securities trading policy ( Policy ) sets out the policy of the Company regarding the tradin
by Board Resolution on: securities trading policy (Policy) sets out the policy of the Company regarding the trading in Company securities. In this policy applies to all Executive and Non-executive directors, officers and employees of the Company (including those defined as Key
Read more →IMRNImmuron Approved to Commence Clinical Study in C.Difficile Infection (CDI)
Final approval for key first in-human Clinical Study for CDI treatment, by Israeli Ministry of Health An estimated 28,000 patients die each year from CDI infections in the USA alone Study of 60 CDI patients to commence at Jerusalem’s Hadassah Medical Centre in Sept 2017 Study
Read more →IMRNImmuron Presents NASH Interim Results at BioShares Conference Melbourne, Australia, 7 August 2017: Australian biopharmaceutical company, Immuron Limited (ASX:IMC; NASDAQ:IMRN), is please to provide investors with a copy
Presents NASH Interim Results at BioShares Conference Australia, 7 August 2017: Australian biopharmaceutical company, Immuron Limited (ASX:IMC; NASDAQ:IMRN), is please to provide investors with a copy of its recent presentation slide deck showcased at the 2017 BioShares Biotech
Read more →IMRNImmuron Announces Management Changes Melbourne, Australia, 3 August 2017: Australian biopharmaceutical company, Immuron Limited (ASX: IMC; NASDAQ: IMRN), today announced that the Company's CEO Mr Thomas Liquard has resig
Announces Management Changes Australia, 3 August 2017: Australian biopharmaceutical company, Immuron Limited (ASX: IMC; NASDAQ: IMRN), today announced that the Company's CEO Mr Thomas Liquard has resigned from the Company due to personal reasons, and will be replaced in the in
Read more →IMRNImmuron Expands on Preliminary Success
Immuron Expands on Preliminary Success Phase II Study in NASH Treatment with Australia, 13 July 2017: Australian biopharmaceutical company, Immuron Limited (ASX:IMC; NASDAQ:IMRN), is pleased to expand on the preliminary announcement of the interim analysis results recently rep
Read more →IMRNII Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety and Tolerability
II Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety and Tolerability Trial to Continue to Completion Australia, 10 July 2017: Australian biopharmaceutical company, Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce safety and e
Read more →IMRNUNDERWRITING AGREEMENT between IMMURON LIMITED and JOSEPH GUNNAR & CO., LLC and RODMAN & RENSHAW, A UNIT OF H.C. WAINWRIGHT & CO., LLC as Representatives of the Several Underwriters IMMURON LIMITED UNDERWRITING AGREEMENT
UNDERWRITING AGREEMENT JOSEPH GUNNAR & CO., LLC A UNIT OF H.C. WAINWRIGHT & CO., LLC as Representatives of the Several Underwriters UNDERWRITING AGREEMENT Joseph Gunnar & Co., LLC 30 Broad Street, 11th Floor Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC 430 Park
Read more →IMRNImmuron Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing – Raising US $6.1 Million
MELBOURNE, Australia, June 08, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN), today announced the pricing of its initial public offering in the United States of 610,000 American Depository Shares ("ADSs") and warrants to pur
Read more →IMRNImmuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies
Significant and clear beneficial biological effect of IMM-124E in the Acute Colitis model Results add to the already existing body of evidence of IMM-124E’s strong anti-inflammatory properties MELBOURNE, Australia, April 18, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical
Read more →IMRNImmuron Completes Phase II NASH Clinical Trial Recruitment
MELBOURNE, Australia, Feb. 20, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC), an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products to target immune-mediated diseases, today announced that the Company’s IMM-124E Phase II
Read more →IMRNImmuron Initiates NASH MOA Studies with SanyalBio and with Duke University
MELBOURNE, Australia, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical Company Immuron Limited (ASX:IMC) is pleased to announce the initiation of several studies designed to add to the growing body of evidence supporting the unique mechanism of action (MOA) of IMM-1
Read more →IMRNImmuron Files F-1 with the SEC
MELBOURNE, Australia, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Australian biopharmaceutical Company, Immuron Limited (ASX:IMC), is pleased to announce today that it filed its Registration Statement on Form F-1 with the United States Securities and Exchange Commission (SEC) relating to t
Read more →IMRNImmuron Receives $1.59M R&D Tax Concession Refund
MELBOURNE, Australia, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of $1.6 million for eligible re
Read more →IMRNImmuron Announces Availability of RedChip Conference Presentation
MELBOURNE, Australia, July 25, 2016 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (OTCQB:IMROY) announces the availability of its presentation from RedChip’s Small Stocks, Big Money Investor Conference. The replay of the Company’s presentation and Q&A session can be viewed at htt
Read more →IMRNImmuron to Cooperate with Leading Australian Universities on Autism Research
MELBOURNE, Australia, July 20, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company, Immuron Limited (ASX:IMC) (OTCQB:IMROY), today announced it has formed a strategic partnership with three leading Australian Research Institutes to understand how the genetic
Read more →IMRNImmuron Rights Issue Raises $5.33M
MELBOURNE, Australia, July 07, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY), is pleased to announce that the Company has received strong support from its existing shareholders and new investors for the Rights Iss
Read more →IMRNImmuron Significantly Expands US Distribution Reach with McKesson Agreement
MELBOURNE, Australia, June 29, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY), today announced that the Company has executed a distribution agreement with McKesson Corporation, the worldwide leader in the distribut
Read more →IMRNImmuron Announces E-Commerce Agreement with QBID in China
MELBOURNE, Australia, June 24, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY) today announced it has entered into a distribution agreement with QBID, one of the leaders in Australia-China e-commerce. Both Travelan
Read more →IMRNImmuron Signs Shigella Vaccine Development Agreement with US Army
MELBOURNE, Australia, June 23, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY), is pleased to announce that the Company has executed Research and Development Collaboration Agreement for the development of a Shigella
Read more →IMRNImmuron Announces Statistically Significant Results of Triple-Action Anti-Infective IMM-529 in Pre-Clinical Clostridium difficile Recurrence Studies
MELBOURNE, Australia, Jan. 12, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (OTCQB:IMROY) today announced that IMM-529, a first-in-class oral therapeutic, successfully demonstrated prevention of Clostridium difficile (C. diffi
Read more →IMRNImmuron Executes U.S. Travelan Sales Agreement With Medico-Mart, Inc.
MELBOURNE, Australia, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (OTCQB:IMROY) is pleased to announce that the Company has executed a non-exclusive distribution agreement with Medico-Mart, Inc. of Waukesha, Wisconsin. The terms and conditions of the agreement wil
Read more →IMRNImmuron Executes US Travelan Sales Partnership With TravelCare WorldWide
MELBOURNE, Australia, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (OTCQB:IMROY) is pleased to announce that the company has executed a partnership agreement with TravelCare WorldWide LLC (TravelCare) of Lone Tree, Colorado for the sale of Travelan throughout its t
Read more →IMRNImmuron Limited Starts NASH Companion Diagnostic Collaboration With OWL S.L.
MELBOURNE, Australia, Nov. 09, 2015 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (OTCQB:IMROY) and One Way Liver S.L. (OWL Metabolomics), a leader in the field of metabolomics and liver diseases diagnostics, have signed a collaboration agreement to evaluate and validate the effi
Read more →Competitive Position
How IMRN ranks across every disease it competes inCompetitive Position is a premium feature
See how IMRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial